0001295947--03-31 2021 Q3 FALSE—0001295947 2020-04-01 2020-12-31 xbrli:shares 0001295947 2021-01-29 iso4217:USD 0001295947 us-gaap:ProductMember 2020-10-01 2020-12-31 0001295947 us-gaap:ProductMember 2019-10-01 2019-12-31 0001295947 us-gaap:ProductMember 2020-04-01 2020-12-31 0001295947 us-gaap:ProductMember 2019-04-01 2019-12-31 0001295947 us-gaap:ProductAndServiceOtherMember 2020-10-01 2020-12-31 0001295947 us-gaap:ProductAndServiceOtherMember 2019-10-01 2019-12-31 0001295947 us-gaap:ProductAndServiceOtherMember 2020-04-01 2020-12-31 0001295947 us-gaap:ProductAndServiceOtherMember 2019-04-01 2019-12-31 0001295947 2020-10-01 2020-12-31 0001295947 2019-10-01 2019-12-31 0001295947 2019-04-01 2019-12-31 iso4217:USD xbrli:shares 0001295947 2020-12-31 0001295947 2020-03-31 0001295947 us-gaap:CommonStockMember 2020-09-30 0001295947 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001295947 us-gaap:TreasuryStockMember 2020-09-30 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001295947 us-gaap:RetainedEarningsMember 2020-09-30 0001295947 2020-09-30 0001295947 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001295947 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001295947 us-gaap:TreasuryStockMember 2020-10-01 2020-12-31 0001295947 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0001295947 us-gaap:CommonStockMember 2020-12-31 0001295947 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001295947 us-gaap:TreasuryStockMember 2020-12-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001295947 us-gaap:RetainedEarningsMember 2020-12-31 0001295947 us-gaap:CommonStockMember 2019-09-30 0001295947 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001295947 us-gaap:TreasuryStockMember 2019-09-30 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001295947 us-gaap:RetainedEarningsMember 2019-09-30 0001295947 2019-09-30 0001295947 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001295947 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001295947 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0001295947 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2019-12-31 0001295947 us-gaap:CommonStockMember 2019-12-31 0001295947 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001295947 us-gaap:TreasuryStockMember 2019-12-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001295947 us-gaap:RetainedEarningsMember 2019-12-31 0001295947 2019-12-31 0001295947 us-gaap:CommonStockMember 2020-03-31 0001295947 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001295947 us-gaap:TreasuryStockMember 2020-03-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001295947 us-gaap:RetainedEarningsMember 2020-03-31 0001295947 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-12-31 0001295947 us-gaap:CommonStockMember 2020-04-01 2020-12-31 0001295947 us-gaap:TreasuryStockMember 2020-04-01 2020-12-31 0001295947 us-gaap:RetainedEarningsMember 2020-04-01 2020-12-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-12-31 0001295947 us-gaap:CommonStockMember 2019-03-31 0001295947 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001295947 us-gaap:TreasuryStockMember 2019-03-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001295947 us-gaap:RetainedEarningsMember 2019-03-31 0001295947 2019-03-31 0001295947 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-12-31 0001295947 us-gaap:CommonStockMember 2019-04-01 2019-12-31 0001295947 us-gaap:TreasuryStockMember 2019-04-01 2019-12-31 0001295947 us-gaap:RetainedEarningsMember 2019-04-01 2019-12-31 0001295947 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-12-31 xbrli:pure 0001295947 pbh:A2019SeniorNotesMember 2020-12-31 0001295947 pbh:A2019SeniorNotesMember 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember 2020-03-31 0001295947 pbh:InternationalOTCHealthcareMember 2020-03-31 0001295947 pbh:NorthAmericanOTCHealthcareMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember 2020-12-31 0001295947 pbh:IndefinitelivedTradenamesMember 2020-03-31 0001295947 pbh:FiniteLivedTradenamesandCustomerRelationshipsMember 2020-03-31 0001295947 pbh:FiniteLivedTradenamesandCustomerRelationshipsMember 2020-04-01 2020-12-31 0001295947 pbh:IndefinitelivedTradenamesMember 2020-04-01 2020-12-31 0001295947 pbh:IndefinitelivedTradenamesMember 2020-12-31 0001295947 pbh:FiniteLivedTradenamesandCustomerRelationshipsMember 2020-12-31 0001295947 srt:MinimumMember 2020-04-01 2020-12-31 0001295947 srt:MaximumMember 2020-04-01 2020-12-31 0001295947 2020-01-01 2020-03-31 0001295947 pbh:GEODISLogisticsLLCMember 2020-12-31 0001295947 us-gaap:SeniorNotesMember pbh:SeniorNotes2016Member 2020-12-31 0001295947 us-gaap:SeniorNotesMember pbh:SeniorNotes2016Member 2020-03-31 0001295947 us-gaap:SeniorNotesMember pbh:A2019SeniorNotesMember 2020-12-31 0001295947 us-gaap:SeniorNotesMember pbh:A2019SeniorNotesMember 2020-03-31 0001295947 pbh:SeniorNotes2012Member pbh:LoansPayableTermB5Member us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-01 2020-12-31 0001295947 pbh:SeniorNotes2012Member pbh:LoansPayableTermB5Member us-gaap:BaseRateMember 2020-04-01 2020-12-31 0001295947 pbh:SeniorNotes2012Member pbh:LoansPayableTermB5Member 2020-12-31 0001295947 pbh:SeniorNotes2012Member pbh:LoansPayableTermB5Member 2020-03-31 0001295947 us-gaap:RevolvingCreditFacilityMember pbh:AblRevolver2012Member 2020-12-31 0001295947 us-gaap:RevolvingCreditFacilityMember pbh:AblRevolver2012Member 2020-03-31 0001295947 us-gaap:RevolvingCreditFacilityMember pbh:AblRevolver2012Member 2020-04-01 2020-12-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001295947 us-gaap:SeniorNotesMember pbh:SeniorNotes2016Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember pbh:SeniorNotes2016Member 2020-12-31 0001295947 us-gaap:SeniorNotesMember pbh:SeniorNotes2016Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember pbh:SeniorNotes2016Member 2020-03-31 0001295947 us-gaap:SeniorNotesMember pbh:A2019SeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember us-gaap:FairValueInputsLevel2Member pbh:A2019SeniorNotesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001295947 us-gaap:SeniorNotesMember pbh:A2019SeniorNotesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember us-gaap:FairValueInputsLevel2Member pbh:A2019SeniorNotesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001295947 us-gaap:LoansPayableMember pbh:LoansPayableTermB4Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LoansPayableMember us-gaap:FairValueInputsLevel2Member pbh:LoansPayableTermB4Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001295947 us-gaap:LoansPayableMember pbh:LoansPayableTermB4Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LoansPayableMember us-gaap:FairValueInputsLevel2Member pbh:LoansPayableTermB4Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001295947 us-gaap:RevolvingCreditFacilityMember pbh:AblRevolver2012Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:RevolvingCreditFacilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember pbh:AblRevolver2012Member 2020-12-31 0001295947 us-gaap:RevolvingCreditFacilityMember pbh:AblRevolver2012Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:RevolvingCreditFacilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember pbh:AblRevolver2012Member 2020-03-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001295947 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 pbh:agreement 0001295947 2020-01-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2020-12-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentLiabilitiesMember 2020-12-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2020-03-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentLiabilitiesMember 2020-03-31 0001295947 us-gaap:InterestRateSwapMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001295947 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0001295947 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2019-10-01 2019-12-31 0001295947 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2020-04-01 2020-12-31 0001295947 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2019-04-01 2019-12-31 0001295947 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-10-01 2020-12-31 0001295947 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-01 2019-12-31 0001295947 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-01 2020-12-31 0001295947 us-gaap:InterestExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-01 2019-12-31 0001295947 us-gaap:InterestRateSwapMember 2020-12-31 pbh:vote 0001295947 us-gaap:RestrictedStockMember 2020-10-01 2020-12-31 0001295947 us-gaap:RestrictedStockMember 2019-10-01 2019-12-31 0001295947 us-gaap:RestrictedStockMember 2020-04-01 2020-12-31 0001295947 us-gaap:RestrictedStockMember 2019-04-01 2019-12-31 0001295947 pbh:ShareRepurchaseProgramMember 2020-10-01 2020-12-31 0001295947 pbh:ShareRepurchaseProgramMember 2019-10-01 2019-12-31 0001295947 pbh:ShareRepurchaseProgramMember 2020-04-01 2020-12-31 0001295947 pbh:ShareRepurchaseProgramMember 2019-04-01 2019-12-31 0001295947 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001295947 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001295947 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-04-01 2020-12-31 0001295947 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-04-01 2020-03-31 0001295947 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001295947 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0001295947 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001295947 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001295947 2019-04-01 2020-03-31 0001295947 us-gaap:StockCompensationPlanMember 2020-10-01 2020-12-31 0001295947 us-gaap:StockCompensationPlanMember 2019-10-01 2019-12-31 0001295947 us-gaap:StockCompensationPlanMember 2020-04-01 2020-12-31 0001295947 us-gaap:StockCompensationPlanMember 2019-04-01 2019-12-31 0001295947 pbh:LongtermEquityIncentivePlan2005Member 2014-05-31 0001295947 pbh:LongtermEquityIncentivePlan2005Member 2014-06-01 2014-06-30 0001295947 2014-05-31 2014-05-31 0001295947 2014-06-01 2014-06-30 0001295947 pbh:LongTermIncentivePlan2020Member 2020-08-04 0001295947 us-gaap:PerformanceSharesMember 2020-05-04 2020-05-04 0001295947 pbh:RestrictedStockUnitsRSUsStockOptionsMember 2020-05-04 2020-05-04 0001295947 us-gaap:EmployeeStockOptionMember 2020-05-04 2020-05-04 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2020-05-04 2020-05-04 0001295947 us-gaap:RestrictedStockUnitsRSUMember srt:DirectorMember 2020-08-04 2020-08-04 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-12-31 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-12-31 0001295947 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001295947 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-04-01 2020-12-31 0001295947 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-04-01 2020-12-31 0001295947 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2019-04-01 2019-12-31 0001295947 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-04-01 2019-12-31 0001295947 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-12-31 0001295947 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-12-31 0001295947 us-gaap:NonqualifiedPlanMember 2020-04-01 2020-12-31 0001295947 us-gaap:QualifiedPlanMember 2020-12-31 0001295947 us-gaap:NonqualifiedPlanMember 2020-12-31 0001295947 us-gaap:SalesMember pbh:TopFiveBrandsMember us-gaap:ProductConcentrationRiskMember 2020-10-01 2020-12-31 0001295947 us-gaap:SalesMember pbh:TopFiveBrandsMember us-gaap:ProductConcentrationRiskMember 2020-04-01 2020-12-31 0001295947 us-gaap:SalesMember pbh:TopFiveBrandsMember us-gaap:ProductConcentrationRiskMember 2019-10-01 2019-12-31 0001295947 us-gaap:SalesMember pbh:TopFiveBrandsMember us-gaap:ProductConcentrationRiskMember 2019-04-01 2019-12-31 0001295947 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember pbh:WalmartMember 2020-10-01 2020-12-31 0001295947 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember pbh:WalmartMember 2020-04-01 2020-12-31 0001295947 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember pbh:WalmartMember 2019-10-01 2019-12-31 0001295947 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember pbh:WalmartMember 2019-04-01 2019-12-31 pbh:manufacturer 0001295947 us-gaap:SupplierConcentrationRiskMember us-gaap:SalesMember 2020-04-01 2020-12-31 0001295947 us-gaap:SupplierConcentrationRiskMember us-gaap:SalesMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:OperatingSegmentsMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember us-gaap:OperatingSegmentsMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:IntersegmentEliminationMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:OperatingSegmentsMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember us-gaap:OperatingSegmentsMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:IntersegmentEliminationMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:OperatingSegmentsMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember us-gaap:OperatingSegmentsMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:IntersegmentEliminationMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:OperatingSegmentsMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember us-gaap:OperatingSegmentsMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:AnalgesicsMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:AnalgesicsMember 2020-10-01 2020-12-31 0001295947 pbh:AnalgesicsMember 2020-10-01 2020-12-31 0001295947 pbh:CoughAndColdMember pbh:NorthAmericanOTCHealthcareMember 2020-10-01 2020-12-31 0001295947 pbh:CoughAndColdMember pbh:InternationalOTCHealthcareMember 2020-10-01 2020-12-31 0001295947 pbh:CoughAndColdMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:WomensHealthMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:WomensHealthMember 2020-10-01 2020-12-31 0001295947 pbh:WomensHealthMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:GastrointestinalMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:GastrointestinalMember 2020-10-01 2020-12-31 0001295947 pbh:GastrointestinalMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:EyeAndEarCareMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:EyeAndEarCareMember 2020-10-01 2020-12-31 0001295947 pbh:EyeAndEarCareMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:DermatologicalsMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:DermatologicalsMember 2020-10-01 2020-12-31 0001295947 pbh:DermatologicalsMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:OralCareMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:OralCareMember 2020-10-01 2020-12-31 0001295947 pbh:OralCareMember 2020-10-01 2020-12-31 0001295947 pbh:OtherOtcMember pbh:NorthAmericanOTCHealthcareMember 2020-10-01 2020-12-31 0001295947 pbh:OtherOtcMember pbh:InternationalOTCHealthcareMember 2020-10-01 2020-12-31 0001295947 pbh:OtherOtcMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember 2020-10-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember 2020-10-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:AnalgesicsMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:AnalgesicsMember 2020-04-01 2020-12-31 0001295947 pbh:AnalgesicsMember 2020-04-01 2020-12-31 0001295947 pbh:CoughAndColdMember pbh:NorthAmericanOTCHealthcareMember 2020-04-01 2020-12-31 0001295947 pbh:CoughAndColdMember pbh:InternationalOTCHealthcareMember 2020-04-01 2020-12-31 0001295947 pbh:CoughAndColdMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:WomensHealthMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:WomensHealthMember 2020-04-01 2020-12-31 0001295947 pbh:WomensHealthMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:GastrointestinalMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:GastrointestinalMember 2020-04-01 2020-12-31 0001295947 pbh:GastrointestinalMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:EyeAndEarCareMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:EyeAndEarCareMember 2020-04-01 2020-12-31 0001295947 pbh:EyeAndEarCareMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:DermatologicalsMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:DermatologicalsMember 2020-04-01 2020-12-31 0001295947 pbh:DermatologicalsMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:OralCareMember 2020-04-01 2020-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:OralCareMember 2020-04-01 2020-12-31 0001295947 pbh:OralCareMember 2020-04-01 2020-12-31 0001295947 pbh:OtherOtcMember pbh:NorthAmericanOTCHealthcareMember 2020-04-01 2020-12-31 0001295947 pbh:OtherOtcMember pbh:InternationalOTCHealthcareMember 2020-04-01 2020-12-31 0001295947 pbh:OtherOtcMember 2020-04-01 2020-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:AnalgesicsMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:AnalgesicsMember 2019-10-01 2019-12-31 0001295947 pbh:AnalgesicsMember 2019-10-01 2019-12-31 0001295947 pbh:CoughAndColdMember pbh:NorthAmericanOTCHealthcareMember 2019-10-01 2019-12-31 0001295947 pbh:CoughAndColdMember pbh:InternationalOTCHealthcareMember 2019-10-01 2019-12-31 0001295947 pbh:CoughAndColdMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:WomensHealthMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:WomensHealthMember 2019-10-01 2019-12-31 0001295947 pbh:WomensHealthMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:GastrointestinalMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:GastrointestinalMember 2019-10-01 2019-12-31 0001295947 pbh:GastrointestinalMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:EyeAndEarCareMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:EyeAndEarCareMember 2019-10-01 2019-12-31 0001295947 pbh:EyeAndEarCareMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:DermatologicalsMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:DermatologicalsMember 2019-10-01 2019-12-31 0001295947 pbh:DermatologicalsMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:OralCareMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:OralCareMember 2019-10-01 2019-12-31 0001295947 pbh:OralCareMember 2019-10-01 2019-12-31 0001295947 pbh:OtherOtcMember pbh:NorthAmericanOTCHealthcareMember 2019-10-01 2019-12-31 0001295947 pbh:OtherOtcMember pbh:InternationalOTCHealthcareMember 2019-10-01 2019-12-31 0001295947 pbh:OtherOtcMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember 2019-10-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember 2019-10-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:AnalgesicsMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:AnalgesicsMember 2019-04-01 2019-12-31 0001295947 pbh:AnalgesicsMember 2019-04-01 2019-12-31 0001295947 pbh:CoughAndColdMember pbh:NorthAmericanOTCHealthcareMember 2019-04-01 2019-12-31 0001295947 pbh:CoughAndColdMember pbh:InternationalOTCHealthcareMember 2019-04-01 2019-12-31 0001295947 pbh:CoughAndColdMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:WomensHealthMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:WomensHealthMember 2019-04-01 2019-12-31 0001295947 pbh:WomensHealthMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:GastrointestinalMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:GastrointestinalMember 2019-04-01 2019-12-31 0001295947 pbh:GastrointestinalMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:EyeAndEarCareMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:EyeAndEarCareMember 2019-04-01 2019-12-31 0001295947 pbh:EyeAndEarCareMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:DermatologicalsMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:DermatologicalsMember 2019-04-01 2019-12-31 0001295947 pbh:DermatologicalsMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember pbh:OralCareMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember pbh:OralCareMember 2019-04-01 2019-12-31 0001295947 pbh:OralCareMember 2019-04-01 2019-12-31 0001295947 pbh:OtherOtcMember pbh:NorthAmericanOTCHealthcareMember 2019-04-01 2019-12-31 0001295947 pbh:OtherOtcMember pbh:InternationalOTCHealthcareMember 2019-04-01 2019-12-31 0001295947 pbh:OtherOtcMember 2019-04-01 2019-12-31 0001295947 pbh:NorthAmericanOTCHealthcareMember 2019-04-01 2019-12-31 0001295947 pbh:InternationalOTCHealthcareMember 2019-04-01 2019-12-31 0001295947 country:US 2020-10-01 2020-12-31 0001295947 country:US 2019-10-01 2019-12-31 0001295947 country:US 2020-04-01 2020-12-31 0001295947 country:US 2019-04-01 2019-12-31 0001295947 us-gaap:NonUsMember 2020-10-01 2020-12-31 0001295947 us-gaap:NonUsMember 2019-10-01 2019-12-31 0001295947 us-gaap:NonUsMember 2020-04-01 2020-12-31 0001295947 us-gaap:NonUsMember 2019-04-01 2019-12-31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2020

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to _____

Commission File Number: 001-32433
PRESTIGE CONSUMER HEALTHCARE INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware |  | 20-1297589
(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.)

660 White Plains Road
Tarrytown, New York 10591
(Address of Principal Executive Offices) (Zip Code)
(914) 524-6800

(Registrant's Telephone Number, Including Area Code)
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.01 per share | PBH | New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer | ☒ |  |  | Accelerated Filer | ☐
Non-Accelerated Filer | ☐ |  |  | Smaller Reporting Company | ☐
|  |  |  | Emerging Growth Company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
As of January 29, 2021, there were 49,864,752 shares of common stock outstanding.

Prestige Consumer Healthcare Inc.
Form 10-Q
Index

PART I. | FINANCIAL INFORMATION |
Item 1. | Financial Statements |
| Condensed Consolidated Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2020 and 2019 (unaudited) | 2
| Condensed Consolidated Balance Sheets as of December 31, 2020 and March 31, 2020 (unaudited) | 3
| Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended December 31, 2020 and 2019 (unaudited) | 4
| Condensed Consolidated Statements of Cash Flows for the nine months ended December 31, 2020 and 2019 (unaudited) | 6
| Notes to Condensed Consolidated Financial Statements (unaudited) | 7
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 25
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 37
Item 4. | Controls and Procedures | 37
PART II. | OTHER INFORMATION |
Item 1A. | Risk Factors | 38
Item 2. | Issuer Purchases of Equity Securities | 38
Item 6. | Exhibits | 39
| Signatures | 40

Trademarks and Trade Names
Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Consumer Healthcare Inc. or its subsidiaries, as the case may be. We have italicized our trademarks or trade names when they appear in this Quarterly Report on Form 10-Q.
-1-

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income and Comprehensive Income
(Unaudited)

| Three Months Ended December 31, |  | Nine Months Ended December 31,
(In thousands, except per share data) | 2020 |  | 2019 |  | 2020 |  | 2019
Revenues |  |  |  |  |  |  |
Net sales | $ | 238,779 |  |  | $ | 241,545 |  |  | $ | 705,572 |  |  | $ | 711,729 |
Other revenues | 9 |  |  | 7 |  |  | 32 |  |  | 46 |
Total revenues | 238,788 |  |  | 241,552 |  |  | 705,604 |  |  | 711,775 |
Cost of Sales |  |  |  |  |  |  |
Cost of sales excluding depreciation | 98,260 |  |  | 102,900 |  |  | 290,623 |  |  | 300,318 |
Cost of sales depreciation | 1,641 |  |  | 1,157 |  |  | 4,565 |  |  | 3,144 |
Cost of sales | 99,901 |  |  | 104,057 |  |  | 295,188 |  |  | 303,462 |
Gross profit | 138,887 |  |  | 137,495 |  |  | 410,416 |  |  | 408,313 |
Operating Expenses |  |  |  |  |  |  |
Advertising and marketing | 38,081 |  |  | 33,559 |  |  | 104,172 |  |  | 107,027 |
General and administrative | 21,395 |  |  | 21,308 |  |  | 61,717 |  |  | 65,528 |
Depreciation and amortization | 5,968 |  |  | 6,224 |  |  | 18,062 |  |  | 18,520 |
Total operating expenses | 65,444 |  |  | 61,091 |  |  | 183,951 |  |  | 191,075 |
Operating income | 73,443 |  |  | 76,404 |  |  | 226,465 |  |  | 217,238 |
Other (income) expense |  |  |  |  |  |  |
Interest expense, net | 20,138 |  |  | 24,275 |  |  | 63,345 |  |  | 73,772 |
Loss on extinguishment of debt | — |  |  | 2,155 |  |  | — |  |  | 2,155 |
Other (income) expense, net | (371) |  |  | (580) |  |  | (620) |  |  | 695 |
Total other expense, net | 19,767 |  |  | 25,850 |  |  | 62,725 |  |  | 76,622 |
Income before income taxes | 53,676 |  |  | 50,554 |  |  | 163,740 |  |  | 140,616 |
Provision for income taxes | 12,803 |  |  | 12,496 |  |  | 34,572 |  |  | 35,381 |
Net income | $ | 40,873 |  |  | $ | 38,058 |  |  | $ | 129,168 |  |  | $ | 105,235 |
Earnings per share: |  |  |  |  |  |  |
Basic | $ | 0.81 |  |  | $ | 0.76 |  |  | $ | 2.57 |  |  | $ | 2.07 |
Diluted | $ | 0.81 |  |  | $ | 0.75 |  |  | $ | 2.55 |  |  | $ | 2.05 |
Weighted average shares outstanding: |  |  |  |  |  |  |
Basic | 50,212 |  |  | 50,378 |  |  | 50,268 |  |  | 50,840 |
Diluted | 50,561 |  |  | 50,831 |  |  | 50,635 |  |  | 51,226 |
Comprehensive income, net of tax: |  |  |  |  |  |  |
Currency translation adjustments | 8,184 |  |  | 3,497 |  |  | 22,439 |  |  | (311) |
Unrealized gain on interest rate swaps | 1,053 |  |  | — |  |  | 2,347 |  |  | — |
Unrecognized net gain on pension plans | 2,334 |  |  | — |  |  | 2,334 |  |  | — |
Net gain on pension distribution reclassified to net income | (190) |  |  | — |  |  | (190) |  |  | — |
Total other comprehensive income (loss) | 11,381 |  |  | 3,497 |  |  | 26,930 |  |  | (311) |
Comprehensive income | $ | 52,254 |  |  | $ | 41,555 |  |  | $ | 156,098 |  |  | $ | 104,924 |

See accompanying notes.
-2-

Prestige Consumer Healthcare Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

(In thousands) | December 31, 2020 |  | March 31, 2020
Assets |  |  |
Current assets |  |  |
Cash and cash equivalents | $ | 62,103 |  |  | $ | 94,760 |
Accounts receivable, net of allowance of $19,025 and $20,194, respectively | 116,004 |  |  | 150,517 |
Inventories | 117,011 |  |  | 116,026 |
Prepaid expenses and other current assets | 6,093 |  |  | 4,351 |
Total current assets | 301,211 |  |  | 365,654 |
Property, plant and equipment, net | 68,620 |  |  | 55,988 |
Operating lease right-of-use assets | 24,867 |  |  | 28,888 |
Finance lease right-of-use assets, net | 9,628 |  |  | 5,842 |
Goodwill | 579,559 |  |  | 575,179 |
Intangible assets, net | 2,481,725 |  |  | 2,479,391 |
Other long-term assets | 3,159 |  |  | 2,963 |
Total Assets | $ | 3,468,769 |  |  | $ | 3,513,905 |
Liabilities and Stockholders' Equity |  |  |
Current liabilities |  |  |
Accounts payable | $ | 29,114 |  |  | $ | 62,375 |
Accrued interest payable | 22,312 |  |  | 9,911 |
Operating lease liabilities, current portion | 5,599 |  |  | 5,612 |
Finance lease liabilities, current portion | 2,569 |  |  | 1,220 |
Other accrued liabilities | 66,569 |  |  | 70,763 |
Total current liabilities | 126,163 |  |  | 149,881 |
Long-term debt, net | 1,548,692 |  |  | 1,730,300 |
Deferred income tax liabilities | 424,364 |  |  | 407,812 |
Long-term operating lease liabilities, net of current portion | 21,017 |  |  | 24,877 |
Long-term finance lease liabilities, net of current portion | 7,471 |  |  | 4,626 |
Other long-term liabilities | 17,841 |  |  | 25,438 |
Total Liabilities | 2,145,548 |  |  | 2,342,934 |
Commitments and Contingencies — Note 16 |  |  |
Stockholders' Equity |  |  |
Preferred stock - $0.01 par value |  |  |
Authorized - 5,000 shares |  |  |
Issued and outstanding - None | — |  |  | — |
Common stock - $0.01 par value |  |  |
Authorized - 250,000 shares |  |  |
Issued - 53,945 shares at December 31, 2020 and 53,805 shares at March 31, 2020 | 539 |  |  | 538 |
Additional paid-in capital | 495,383 |  |  | 488,116 |
Treasury stock, at cost - 4,033 shares at December 31, 2020 and 3,719 shares at March 31, 2020 | (128,739) |  |  | (117,623) |
Accumulated other comprehensive loss, net of tax | (17,231) |  |  | (44,161) |
Retained earnings | 973,269 |  |  | 844,101 |
Total Stockholders' Equity | 1,323,221 |  |  | 1,170,971 |
Total Liabilities and Stockholders' Equity | $ | 3,468,769 |  |  | $ | 3,513,905 |

See accompanying notes.
-3-

Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(Unaudited)

| Three Months Ended December 31, 2020
| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income (Loss) |  |  |  | Retained Earnings |  | Totals
(In thousands) | Shares |  | Par Value |  |  | Shares |  | Amount |  |  |  |
Balances at September 30, 2020 | 53,941 |  |  | $ | 539 |  |  | $ | 493,756 |  |  | 3,779 |  |  | $ | (119,862) |  |  | $ | (28,612) |  |  |  |  | $ | 932,396 |  |  | $ | 1,278,217 |
Stock-based compensation | — |  |  | — |  |  | 1,588 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 1,588 |
Exercise of stock options | 4 |  |  | — |  |  | 39 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 39 |
Treasury share repurchases | — |  |  | — |  |  | — |  |  | 254 |  |  | (8,877) |  |  | — |  |  |  |  | — |  |  | (8,877) |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 40,873 |  |  | 40,873 |
Comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 11,381 |  |  |  |  | — |  |  | 11,381 |
Balances at December 31, 2020 | 53,945 |  |  | $ | 539 |  |  | $ | 495,383 |  |  | 4,033 |  |  | $ | (128,739) |  |  | $ | (17,231) |  |  |  |  | $ | 973,269 |  |  | $ | 1,323,221 |

| Three Months Ended December 31, 2019
| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income (Loss) |  |  |  | Retained Earnings |  | Totals
(In thousands) | Shares |  | Par Value |  |  | Shares |  | Amount |  |  |  |
Balances at September 30, 2019 | 53,755 |  |  | $ | 537 |  |  | $ | 483,595 |  |  | 3,523 |  |  | $ | (110,784) |  |  | $ | (29,555) |  |  |  |  | $ | 768,997 |  |  | $ | 1,112,790 |
Stock-based compensation | — |  |  | — |  |  | 1,780 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 1,780 |
Exercise of stock options | 18 |  |  | — |  |  | 463 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 463 |
Issuance of shares related to restricted stock | 6 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | — |
Treasury share repurchases | — |  |  | — |  |  | — |  |  | 2 |  |  | (94) |  |  | — |  |  |  |  | — |  |  | (94) |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 38,058 |  |  | 38,058 |
Comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,497 |  |  |  |  | — |  |  | 3,497 |
Balances at December 31, 2019 | 53,779 |  |  | $ | 537 |  |  | $ | 485,838 |  |  | 3,525 |  |  | $ | (110,878) |  |  | $ | (26,058) |  |  |  |  | $ | 807,055 |  |  | $ | 1,156,494 |

-4-

| Nine Months Ended December 31, 2020
| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income (Loss) |  |  |  | Retained Earnings |  | Totals
(In thousands) | Shares |  | Par Value |  |  | Shares |  | Amount |  |  |  |
Balances at March 31, 2020 | 53,805 |  |  | $ | 538 |  |  | $ | 488,116 |  |  | 3,719 |  |  | $ | (117,623) |  |  | $ | (44,161) |  |  |  |  | $ | 844,101 |  |  | $ | 1,170,971 |
Stock-based compensation | — |  |  | — |  |  | 5,944 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 5,944 |
Exercise of stock options | 66 |  |  | — |  |  | 1,324 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 1,324 |
Issuance of shares related to restricted stock | 74 |  |  | 1 |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | — |
Treasury share repurchases | — |  |  | — |  |  | — |  |  | 314 |  |  | (11,116) |  |  | — |  |  |  |  | — |  |  | (11,116) |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 129,168 |  |  | 129,168 |
Comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 26,930 |  |  |  |  | — |  |  | 26,930 |
Balances at December 31, 2020 | 53,945 |  |  | $ | 539 |  |  | $ | 495,383 |  |  | 4,033 |  |  | $ | (128,739) |  |  | $ | (17,231) |  |  |  |  | $ | 973,269 |  |  | $ | 1,323,221 |

| Nine Months Ended December 31, 2019
| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  |  |  | Retained Earnings |  | Totals
(In thousands) | Shares |  | Par Value |  |  | Shares |  | Amount |  |  |  |
Balances at March 31, 2019 | 53,670 |  |  | $ | 536 |  |  | $ | 479,150 |  |  | 1,871 |  |  | $ | (59,928) |  |  | $ | (25,747) |  |  |  |  | $ | 701,820 |  |  | $ | 1,095,831 |
Stock-based compensation | — |  |  | — |  |  | 5,682 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 5,682 |
Exercise of stock options | 36 |  |  | — |  |  | 1,007 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 1,007 |
Issuance of shares related to restricted stock | 73 |  |  | 1 |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | — |
Treasury share repurchases | — |  |  | — |  |  | — |  |  | 1,654 |  |  | (50,950) |  |  | — |  |  |  |  | — |  |  | (50,950) |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 105,235 |  |  | 105,235 |
Comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (311) |  |  |  |  | — |  |  | (311) |
Balances at December 31, 2019 | 53,779 |  |  | $ | 537 |  |  | $ | 485,838 |  |  | 3,525 |  |  | $ | (110,878) |  |  | $ | (26,058) |  |  |  |  | $ | 807,055 |  |  | $ | 1,156,494 |

See accompanying notes.
-5-

Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

| Nine Months Ended December 31,
(In thousands) | 2020 |  | 2019
Operating Activities |  |  |
Net income | $ | 129,168 |  |  | $ | 105,235 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
Depreciation and amortization | 22,627 |  |  | 21,664 |
Loss on disposal of property and equipment | 210 |  |  | 184 |
Deferred income taxes | 7,970 |  |  | 7,383 |
Amortization of debt origination costs | 3,569 |  |  | 2,766 |
Stock-based compensation costs | 5,944 |  |  | 5,682 |
Loss on extinguishment of debt | — |  |  | 2,155 |
Non-cash operating lease cost | 5,362 |  |  | 6,117 |
Other | 937 |  |  | 34 |
Changes in operating assets and liabilities: |  |  |
Accounts receivable | 36,725 |  |  | 4,624 |
Inventories | 1,269 |  |  | (817) |
Prepaid expenses and other current assets | (1,439) |  |  | (879) |
Accounts payable | (35,789) |  |  | (6,091) |
Accrued liabilities | 8,236 |  |  | 20,724 |
Operating lease liabilities | (5,085) |  |  | (6,430) |
Other | (3,184) |  |  | (1,353) |
Net cash provided by operating activities | 176,520 |  |  | 160,998 |
Investing Activities |  |  |
Purchases of property, plant and equipment | (17,347) |  |  | (9,055) |
Escrow receipt | — |  |  | 750 |
Net cash used in investing activities | (17,347) |  |  | (8,305) |
Financing Activities |  |  |
Proceeds from issuance of 5.125% Senior Notes | — |  |  | 400,000 |
Repayment of 5.375% Senior Notes | — |  |  | (400,000) |
Term loan repayments | (130,000) |  |  | (21,000) |
Borrowings under revolving credit agreement | 15,000 |  |  | 45,000 |
Repayments under revolving credit agreement | (70,000) |  |  | (120,000) |
Payment of debt costs | — |  |  | (5,793) |
Payments of finance leases | (918) |  |  | (252) |
Proceeds from exercise of stock options | 1,324 |  |  | 1,007 |
Fair value of shares surrendered as payment of tax withholding | (1,242) |  |  | (974) |
Repurchase of common stock | (9,874) |  |  | (49,976) |
Net cash used in financing activities | (195,710) |  |  | (151,988) |
Effects of exchange rate changes on cash and cash equivalents | 3,880 |  |  | 356 |
(Decrease) increase in cash and cash equivalents | (32,657) |  |  | 1,061 |
Cash and cash equivalents - beginning of period | 94,760 |  |  | 27,530 |
Cash and cash equivalents - end of period | $ | 62,103 |  |  | $ | 28,591 |
Interest paid | $ | 46,927 |  |  | $ | 66,305 |
Income taxes paid | $ | 29,677 |  |  | $ | 21,212 |

See accompanying notes.
-6-

Prestige Consumer Healthcare Inc.
Notes to Condensed Consolidated Financial Statements (unaudited)
1. Business and Basis of Presentation
Nature of Business
Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada), and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements.
Coronavirus Outbreak
In January 2020, the World Health Organization ("WHO") announced a global health crisis due to a new strain of coronavirus ("COVID-19"). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. This pandemic is affecting the United States and global economies, including causing significant volatility in the global economy and resulting in materially reduced economic activity since early 2020. The COVID-19 pandemic and the corresponding government responses have also led to increased unemployment, which led to a reduction in consumer spending. Economic conditions are, and we expect that they will continue to be, highly volatile and uncertain and could continue to reduce demand for our products and put downward pressure on prices. We did see an increase in sales at the end of March 2020 related to shelter-at-home restrictions as we believe consumers stocked up as a result of COVID-19, followed by a temporary but significant decline in consumption in the first quarter. Since then, we have seen more stable consumer consumption and customer orders. Sales have varied throughout the year with some categories positively impacted (for instance, Women’s Health, Oral Care and Dermatological) and some categories negatively impacted (for instance, Cough & Cold, and Gastrointestinal). The positively impacted categories benefited from the consumer shift to over-the-counter healthcare products as consumers increased their focus on hygiene and self-care at home related to COVID-19. The declining categories were impacted by reduced incidence levels and usage rates due to shelter-at-home restrictions and limited travel related to COVID-19. Early in our first quarter of fiscal 2021, we received reports of an increase in absenteeism at our distribution center and with some of our suppliers; however, we have not experienced a material disruption to our overall supply chain to date. We have continued to see changes in the purchasing patterns of our consumers, including the frequency of visits by consumers to retailers and a shift in many markets to purchasing our products online. To date the pandemic has not had a material negative impact on our operations, overall demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change in this dynamic, unprecedented environment. If the outbreak continues to spread, it may materially affect our operations and those of third parties on which we rely, including causing disruptions in the supply and distribution of our products. We may need to limit operations and may experience material limitations in employee resources. The extent to which COVID-19 impacts our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, and the actions to contain COVID-19 or treat its impact, among others. We do not yet know the full extent of its impacts on our business or the global economy. However, these effects could have a material, adverse impact on our liquidity, capital resources, and results of operations and those of the third parties on which we rely.
Basis of Presentation
The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2021) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the nine months ended December 31, 2020 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2021. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.
-7-

Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Recently Adopted Accounting Pronouncements
In August 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820, with a particular focus on Level 3 investments, by eliminating certain required disclosures and incorporating others. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We adopted this standard effective April 1, 2020, and the adoption did not have a material impact on our Consolidated Financial Statements.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments (with subsequent targeted amendments). The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The guidance requires entities to utilize an expected credit loss model for certain financial instruments, including most trade receivables, which replaces the incurred credit loss model previously used. Under this new model, we are required to recognize estimated credit losses expected to occur over time using a broad range of information including historical information, current conditions and reasonable and supportable forecasts. The amendments in these updates were effective for us in the first quarter of our fiscal year 2021. We adopted this standard effective April 1, 2020, and the adoption did not have a material impact on our Consolidated Financial Statements.
Recently Issued Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by eliminating certain required disclosures and incorporating others. The amendments are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this update eliminate the need for an organization to analyze whether certain exceptions apply for tax purposes. It also simplifies GAAP for certain taxes. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The amendments in this update provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. An entity may elect to apply the amendments prospectively through December 31, 2022. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
2. Inventories
Inventories consist of the following:

(In thousands) | December 31, 2020 |  | March 31, 2020
Components of Inventories |  |  |
Packaging and raw materials | $ | 8,370 |  |  | $ | 9,803 |
Work in process | 321 |  |  | 355 |
Finished goods | 108,320 |  |  | 105,868 |
Inventories | $ | 117,011 |  |  | $ | 116,026 |

-8-

Inventories are carried and depicted above at the lower of cost or net realizable value, which includes a reduction in inventory values of $4.1 million and $6.5 million at December 31, 2020 and March 31, 2020, respectively, related to obsolete and slow-moving inventory.
3. Goodwill
A reconciliation of the activity affecting goodwill by operating segment is as follows:

(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Balance - March 31, 2020 |  |  |  |  |  |  |
| Goodwill | $ | 710,354 |  |  | $ | 28,536 |  |  |  |  | $ | 738,890 |
| Accumulated impairment loss | (163,711) |  |  | — |  |  |  |  | (163,711) |
Balance - March 31, 2020 | 546,643 |  |  | 28,536 |  |  |  |  | 575,179 |
| Effects of foreign currency exchange rates | — |  |  | 4,380 |  |  |  |  | 4,380 |
Balance - December 31, 2020 |  |  |  |  |  |  |
| Goodwill | 710,354 |  |  | 32,916 |  |  |  |  | 743,270 |
| Accumulated impairment loss | (163,711) |  |  | — |  |  |  |  | (163,711) |
Balance - December 31, 2020 | $ | 546,643 |  |  | $ | 32,916 |  |  |  |  | $ | 579,559 |

On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. On February 29, 2020, the date of our annual impairment review, there were no indicators of impairment as a result of the analysis and, accordingly, no impairment charge was taken on our March 31, 2020 financial statements. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 29, 2020 as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increasing competition, changing consumer preferences, technical advances, or reductions in advertising and marketing may require an impairment charge to be recorded in the future. We continuously monitor events which could trigger an interim impairment analysis, which included the impact of COVID-19 for the period ended December 31, 2020. As of December 31, 2020, we determined no events have occurred that would indicate potential impairment of goodwill. However, the continued duration and severity of COVID-19 may result in future impairment charges as the prolonged pandemic could have an impact on our results due to changes in consumer habits. This could result in changes to the assumptions utilized in the annual impairment analysis to determine the estimated fair value of our goodwill, including long-term growth rates and discount rates.
-9-

4. Intangible Assets, net
A reconciliation of the activity affecting intangible assets, net is as follows:

(In thousands) | Indefinite- Lived Trademarks |  | Finite-Lived Trademarks and Customer Relationships |  | Totals
Gross Carrying Amounts |  |  |  |  |
Balance — March 31, 2020 | $ | 2,265,331 |  |  | $ | 389,801 |  |  | $ | 2,655,132 |
Tradename impairment | — |  |  | (1,186) |  |  | (1,186) |
Effects of foreign currency exchange rates | 17,800 |  |  | 752 |  |  | 18,552 |
Balance — December 31, 2020 | 2,283,131 |  |  | 389,367 |  |  | 2,672,498 |
Accumulated Amortization |  |  |  |  |
Balance — March 31, 2020 | — |  |  | 175,741 |  |  | 175,741 |
Additions | — |  |  | 14,729 |  |  | 14,729 |
Effects of foreign currency exchange rates | — |  |  | 303 |  |  | 303 |
Balance — December 31, 2020 | — |  |  | 190,773 |  |  | 190,773 |
Intangible assets, net - December 31, 2020 | $ | 2,283,131 |  |  | $ | 198,594 |  |  | $ | 2,481,725 |

Amortization expense was $4.9 million and $14.7 million for the three and nine months ended December 31, 2020, respectively, and $4.9 million and $14.7 million for the three and nine months ended December 31, 2019, respectively.
Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands):

(In thousands) |
Year Ending March 31, | Amount
2021 (remaining three months ended March 31, 2021) | $ | 4,917 |
2022 | 19,670 |
2023 | 19,670 |
2024 | 19,637 |
2025 | 17,592 |
Thereafter | 117,108 |
| $ | 198,594 |

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. On February 29, 2020, the date of our annual impairment review, there were no indicators of impairment as a result of the analysis and, accordingly, no impairment charge was taken on our March 31, 2020 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.
We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and marketing expenses, we may be required to record impairment charges in the future. During the third quarter of 2021, we determined that the fair value of one of our finite-lived intangible assets in our International OTC Healthcare segment,
-10-

Painstop, did not exceed its carrying amount. As such, we recorded an impairment charge of $1.2 million. The decline in the fair value of Painstop was primarily related to a decline in expected future sales due to a regulatory change that now requires Painstop to be prescribed by physicians rather than sold over-the-counter direct to consumers.
We continuously monitor events which could trigger an interim impairment analysis, which included the impact of COVID-19 for the period ended December 31, 2020. As of December 31, 2020, no other events have occurred that would indicate potential additional impairment of intangible assets. However, the continued duration and severity of COVID-19 may result in future impairment charges as the prolonged pandemic could have an impact on our results due to changes in consumer habits. This could result in changes to the assumptions utilized in the annual impairment analysis to determine the estimated fair value of our intangible assets, including long-term growth rates and discount rates.
5. Leases
We lease real estate and equipment for use in our operations.
The components of lease expense for the three and nine months ended December 31, 2020 and 2019 were as follows:

|  | Three Months Ended December 31, |  | Nine Months Ended December 31,
(In thousands) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Finance lease cost: |  |  |  |  |  |  |  |
Amortization of right-of-use assets |  | $ | 629 |  |  | $ | 207 |  |  | $ | 1,397 |  |  | $ | 207 |
Interest on lease liabilities |  | 76 |  |  | 34 |  |  | 185 |  |  | 34 |
Operating lease cost |  | 1,679 |  |  | 2,239 |  |  | 5,068 |  |  | 5,697 |
Short term lease cost |  | 24 |  |  | 28 |  |  | 69 |  |  | 78 |
Variable lease cost |  | 11,220 |  |  | 15,731 |  |  | 35,230 |  |  | 48,396 |
Sublease income |  | (54) |  |  | (833) |  |  | (163) |  |  | (2,607) |
Total net lease cost |  | $ | 13,574 |  |  | $ | 17,406 |  |  | $ | 41,786 |  |  | $ | 51,805 |

As of December 31, 2020, the maturities of lease liabilities were as follows:

(In thousands) |  |  |  |  |  |
Year Ending March 31, |  | Operating Leases |  | Finance Lease |  | Total
2021 (Remaining three months ending March 31, 2021) |  | $ | 1,983 |  |  | $ | 706 |  |  | $ | 2,689 |
2022 |  | 6,557 |  |  | 2,826 |  |  | 9,383 |
2023 |  | 6,293 |  |  | 2,826 |  |  | 9,119 |
2024 |  | 6,303 |  |  | 2,826 |  |  | 9,129 |
2025 |  | 4,132 |  |  | 1,412 |  |  | 5,544 |
Thereafter |  | 4,974 |  |  | — |  |  | 4,974 |
Total undiscounted lease payments |  | 30,242 |  |  | 10,596 |  |  | 40,838 |
Less amount of lease payments representing interest |  | (3,626) |  |  | (556) |  |  | (4,182) |
Total present value of lease payments |  | $ | 26,616 |  |  | $ | 10,040 |  |  | $ | 36,656 |

The weighted average remaining lease term and weighted average discount rate were as follows:

|  |  | December 31, 2020
Weighted average remaining lease term (years) |  |
| Operating leases |  | 4.88
| Finance leases |  | 3.75
Weighted average discount rate |  |
| Operating leases |  | 5.28 | %
| Finance leases |  | 2.98 | %

-11-

Under our Master Services Agreement with GEODIS Logistics LLC ("GEODIS"), GEODIS purchased certain assets for our use that went into service during the three months ended September 30, 2020. The right-of-use ("ROU") asset and lease liability at the commencement of this finance lease was $5.2 million.
6. Other Accrued Liabilities
Other accrued liabilities consist of the following:

(In thousands) | December 31, 2020 |  | March 31, 2020
Accrued marketing costs | $ | 40,377 |  |  | $ | 34,450 |
Accrued compensation costs | 10,901 |  |  | 13,393 |
Accrued broker commissions | 479 |  |  | 1,491 |
Income taxes payable | 294 |  |  | 3,210 |
Accrued professional fees | 3,647 |  |  | 4,183 |
Accrued production costs | 3,229 |  |  | 5,628 |
Accrued sales tax | 228 |  |  | 1,917 |
Other accrued liabilities | 7,414 |  |  | 6,491 |
| $ | 66,569 |  |  | $ | 70,763 |

7. Long-Term Debt
Long-term debt consists of the following, as of the dates indicated:

(In thousands, except percentages) |  | December 31, 2020 |  | March 31, 2020
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. |  | $ | 600,000 |  |  | $ | 600,000 |
2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. |  | 400,000 |  |  | 400,000 |
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a base rate floor of 1.00%, due on January 26, 2024. |  | 560,000 |  |  | 690,000 |
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on December 11, 2024. |  | — |  |  | 55,000 |
Long-term debt |  | 1,560,000 |  |  | 1,745,000 |
Less: unamortized debt costs |  | (11,308) |  |  | (14,700) |
Long-term debt, net |  | $ | 1,548,692 |  |  | $ | 1,730,300 |

At December 31, 2020, we had no balance outstanding on the asset-based revolving credit facility entered into January 31, 2012, as amended (the "2012 ABL Revolver") and a borrowing capacity of $123.3 million.
Interest Rate Swaps:
We currently have two interest rate swaps to hedge a total of $400.0 million of our variable interest debt (see Note 9 for further details).
-12-

As of December 31, 2020, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2024 (the "2016 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows:

(In thousands) |
Year Ending March 31, | Amount
2021 (remaining three months ending March 31, 2021) | $ | — |
2022 |  | — |
2023 |  | — |
2024 |  | 1,160,000 |
2025 |  | — |
Thereafter | 400,000 |
| $ | 1,560,000 |

8. Fair Value Measurements
For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.
FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements, requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:
Level 1 - Quoted market prices for identical instruments in active markets;
Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and
Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant.
The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver and our interest rate swaps are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these instruments at December 31, 2020 and March 31, 2020.

|  | December 31, 2020 |  | March 31, 2020
(In thousands) |  | Carrying Value |  | Fair Value |  | Carrying Value |  | Fair Value
2016 Senior Notes |  | $ | 600,000 |  |  | $ | 613,500 |  |  | $ | 600,000 |  |  | $ | 603,000 |
2019 Senior Notes |  | 400,000 |  |  | 421,000 |  |  | 400,000 |  |  | 386,000 |
2012 Term B-5 Loans |  | 560,000 |  |  | 560,700 |  |  | 690,000 |  |  | 638,250 |
2012 ABL Revolver |  | — |  |  | — |  |  | 55,000 |  |  | 55,000 |
Interest rate swaps |  | 3,269 |  |  | 3,269 |  |  | 6,317 |  |  | 6,317 |

At December 31, 2020 and March 31, 2020, we did not have any assets or liabilities measured in Level 1 or 3.
9. Derivative Instruments
Changes in interest rates expose us to risks. To help us manage these risks, in January 2020 we entered into two interest rate swaps to hedge a total of $400.0 million of our variable interest debt. The fair value of these interest rate swaps is reflected in our Consolidated Balance Sheets in other accrued liabilities and other long-term liabilities. We do not use derivatives for trading purposes.
The following tables summarize the fair values of our derivative instruments as of the end of the periods shown:
-13-

|  | December 31, 2020
(In thousands) |  | Hedge Type |  | Final Settlement Date |  | Notional Amount |  | Other Accrued Liabilities |  | Other Long-Term Liabilities
Interest rate swap |  | Cash flow |  | 1/31/2021 |  | $ | 200,000 |  |  | $ | (224) |  |  | $ | — |
Interest rate swap |  | Cash flow |  | 1/31/2022 |  | $ | 200,000 |  |  | — |  |  | (3,045) |
Total fair value |  |  |  |  |  |  |  | $ | (224) |  |  | $ | (3,045) |

|  | March 31, 2020
(In thousands) |  | Hedge Type |  | Final Settlement Date |  | Notional Amount |  | Other Accrued Liabilities |  | Other Long-Term Liabilities
Interest rate swap |  | Cash flow |  | 1/31/2021 |  | $ | 200,000 |  |  | $ | (1,905) |  |  | $ | — |
Interest rate swap |  | Cash flow |  | 1/31/2022 |  | $ | 200,000 |  |  | — |  |  | (4,412) |
Total fair value |  |  |  |  |  |  |  | $ | (1,905) |  |  | $ | (4,412) |

The following table summarizes our interest rate swaps, net of tax, for the periods shown:

|  |  |  | Three Months Ended December 31, |  | Nine Months Ended December 31,
(In thousands) |  | Location |  | 2020 |  | 2019 |  | 2020 |  | 2019
Gain Recognized in Other Comprehensive Loss (effective portion) |  | Other comprehensive income (loss) |  | $ | 1,053 |  |  | $ | — |  |  | $ | 2,347 |  |  | $ | — |
Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income |  | Interest expense |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Loss Recognized as Expense |  | Interest expense |  | $ | (1,415) |  |  | $ | — |  |  | $ | (3,837) |  |  | $ | — |

We expect pre-tax losses of $3.0 million associated with interest rate swaps, currently reported in accumulated other comprehensive loss, to be reclassified into income over the next twelve months. The amount ultimately realized, however, will differ as interest rates change and the underlying contracts settle.
Counterparty Credit Risk:
Interest rate swaps expose us to counterparty credit risk for non-performance. We manage our exposure to counterparty credit risk by only dealing with counterparties who are substantial international financial institutions with significant experience using such derivative instruments.
10. Stockholders' Equity
We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.
Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through December 31, 2020.
During the three and nine months ended December 31, 2020 and 2019, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following:
-14-

| Three Months Ended December 31, |  | Nine Months Ended December 31,
| 2020 |  | 2019 |  | 2020 |  | 2019
Shares repurchased pursuant to the provisions of the various employee restricted stock awards: |  |  |  |  |  |  |
Number of shares | — |  |  | 2,481 |  |  | 31,117 |  |  | 31,018 |
Average price per share | $ | — |  |  | $37.95 |  | $39.91 |  | $31.39
Total amount repurchased | $ | — |  |  | $0.1 million |  | $1.2 million |  | $1.0 million
Shares repurchased in conjunction with our share repurchase program: |  |  |  |  |  |  |
Number of shares | 253,771 |  |  | — |  |  | 282,636 |  |  | 1,622,544 |
Average price per share | $34.98 |  | $ | — |  |  | $34.93 |  | $30.80
Total amount repurchased | $8.9 million |  | $ | — |  |  | $9.9 million |  | $50.0 million

11. Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss consisted of the following at December 31, 2020 and March 31, 2020:

(In thousands) | December 31, 2020 |  | March 31, 2020
Components of Accumulated Other Comprehensive Loss |  |  |
Cumulative translation adjustment | $ | (16,802) |  |  | $ | (39,241) |
Unrealized loss on interest rate swaps, net of tax of $752 and $1,453, respectively | (2,517) |  |  | (4,864) |
Unrecognized net gain (loss) on pension plans, net of tax of $(624) and $17, respectively | 2,088 |  |  | (56) |
Accumulated other comprehensive loss, net of tax | $ | (17,231) |  |  | $ | (44,161) |

As of December 31, 2020 and March 31, 2020, no amounts were reclassified from accumulated other comprehensive loss into earnings.
12. Earnings Per Share
Basic earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share.
-15-

The following table sets forth the computation of basic and diluted earnings per share:

|  | Three Months Ended December 31, |  | Nine Months Ended December 31,
(In thousands, except per share data) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Numerator |  |  |  |  |  |  |  |
Net income |  | $ | 40,873 |  |  | $ | 38,058 |  |  | $ | 129,168 |  |  | $ | 105,235 |
Denominator |  |  |  |  |  |  |  |
Denominator for basic earnings per share — weighted average shares outstanding |  | 50,212 |  |  | 50,378 |  |  | 50,268 |  |  | 50,840 |
Dilutive effect of unvested restricted stock units and options issued to employees and directors |  | 349 |  |  | 453 |  |  | 367 |  |  | 386 |
Denominator for diluted earnings per share |  | 50,561 |  |  | 50,831 |  |  | 50,635 |  |  | 51,226 |
Earnings per Common Share: |  |  |  |  |  |  |  |
Basic earnings per share |  | $ | 0.81 |  |  | $ | 0.76 |  |  | $ | 2.57 |  |  | $ | 2.07 |
Diluted earnings per share |  | $ | 0.81 |  |  | $ | 0.75 |  |  | $ | 2.55 |  |  | $ | 2.05 |

For the three months ended December 31, 2020 and 2019, there were 0.6 million and 0.6 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2020 and 2019, there were 0.6 million and 0.9 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.
13. Share-Based Compensation
In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, an increase of the maximum number of shares subject to stock options that could be awarded to any one participant under the 2005 Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the 2005 Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, were eligible for grants under the 2005 Plan.
On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. A total of 2,827,210 shares are available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). All future equity awards will be made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan.
The following table provides information regarding our stock-based compensation:

|  | Three Months Ended December 31, |  | Nine Months Ended December 31,
(In thousands) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Pre-tax share-based compensation costs charged against income |  | $ | 1,588 |  |  | $ | 1,780 |  |  | $ | 5,944 |  |  | $ | 5,682 |
Income tax benefit recognized on compensation costs |  | $ | 263 |  |  | $ | 275 |  |  | $ | 826 |  |  | $ | 886 |
Total fair value of options and RSUs vested during the period |  | $ | — |  |  | $ | 465 |  |  | $ | 6,796 |  |  | $ | 7,830 |
Cash received from the exercise of stock options |  | $ | 39 |  |  | $ | 463 |  |  | $ | 1,324 |  |  | $ | 1,007 |
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises |  | $ | 15 |  |  | $ | 105 |  |  | $ | 963 |  |  | $ | 587 |

-16-

At December 31, 2020, there were $7.9 million of unrecognized compensation costs related to unvested share-based compensation arrangements under the 2005 Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted average period of 1 year. At December 31, 2020, there were 2.8 million shares available for issuance under the 2020 Plan.
On May 4, 2020, the Compensation and Talent Management Committee (the "Committee") of our Board of Directors granted 79,070 performance stock units, 73,636 RSUs and stock options to acquire 249,875 shares of our common stock under the 2005 Plan to certain executive officers and employees. Performance units are earned based on achievement of the performance objectives set by the Committee and, if earned, vest in their entirety on the three-year anniversary of the date of grant. In light of the uncertain economic environment, the Committee elected to set the performance objectives applicable to these awards at a later date. The stock options were granted at an exercise price of $39.98 per share, which was equal to the closing price for our common stock on the date of the grant.
A newly appointed independent member of the Board of Directors received a grant under the 2005 Plan of 907 RSUs on May 4, 2020.
On August 4, 2020, each of the independent members of the Board of Directors received a grant of 3,732 RSUs under the 2020 Plan. The RSUs are fully vested upon receipt of the award and will be settled by delivery to each director of one share of our common stock for each vested RSU promptly following the earliest of (i) such director's death, (ii) such director's separation from service or (iii) a change in control of the Company.
Restricted Stock Units
The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:

RSUs |  | Shares (in thousands) |  | Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2019 |  |  |  |
Vested and unvested at March 31, 2019 |  | 413.0 |  |  | $ | 36.58 |
Granted |  | 220.3 |  |  | 31.02 |
Vested and issued |  | (73.0) |  |  | 47.68 |
Forfeited |  | (34.2) |  |  | 35.97 |
Vested and unvested at December 31, 2019 |  | 526.1 |  |  | 32.74 |
Vested at December 31, 2019 |  | 138.3 |  |  | 31.71 |
Nine Months Ended December 31, 2020 |  |  |  |
Vested and unvested at March 31, 2020 |  | 512.1 |  |  | $ | 32.49 |
Granted |  | 179.7 |  |  | 39.82 |
Vested and issued |  | (74.0) |  |  | 44.38 |
Forfeited |  | (4.7) |  |  | 56.11 |
Vested and unvested at December 31, 2020 |  | 613.1 |  |  | 33.02 |
Vested at December 31, 2020 |  | 150.4 |  |  | 31.98 |

-17-

Options
The fair value of each award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:

|  | Nine Months Ended December 31,
|  | 2020 |  | 2019
Expected volatility |  | 32.1% - 32.2% |  | 30.9% - 31.3%
Expected dividends |  | $ | — |  |  | $ | — |
Expected term in years |  | 6.0 to 7.0 |  | 6.0 to 7.0
Risk-free rate |  | 0.5 | % |  | 2.3% to 2.4%
Weighted average grant date fair value of options granted |  | $ | 12.91 |  |  | $ | 10.83 |

A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:

Options |  | Shares (in thousands) |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (years) |  | Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2019 |  |  |  |  |  |  |  |
Outstanding at March 31, 2019 |  | 944.6 |  |  | $ | 38.45 |  |  |  |  |
Granted |  | 302.7 |  |  | 30.53 |  |  |  |  |
Exercised |  | (36.0) |  |  | 27.96 |  |  |  |  |
Forfeited or expired |  | (155.3) |  |  | 41.18 |  |  |  |  |
Outstanding at December 31, 2019 |  | 1,056.0 |  |  | 36.14 |  |  | 6.9 |  | $ | 9,035 |
Vested at December 31, 2019 |  | 602.0 |  |  | 38.90 |  |  | 5.4 |  | $ | 4,756 |
Nine Months Ended December 31, 2020 |  |  |  |  |  |  |  |
Outstanding at March 31, 2020 |  | 1,020.2 |  |  | $ | 35.90 |  |  |  |  |
Granted |  | 249.9 |  |  | 39.98 |  |  |  |  |
Exercised |  | (65.8) |  |  | 20.14 |  |  |  |  |
Forfeited or expired |  | — |  |  | — |  |  |  |  |
Outstanding at December 31, 2020 |  | 1,204.3 |  |  | 37.61 |  |  | 6.8 |  | $ | 3,987 |
Vested at December 31, 2020 |  | 696.2 |  |  | 39.50 |  |  | 5.4 |  | $ | 2,786 |

The aggregate intrinsic value of options exercised during the nine months ended December 31, 2020 was $1.3 million.
14. Income Taxes
On December 22, 2017, the Tax Cuts and Jobs Act was signed into law. The Tax Cuts and Jobs Act, among other things, reduced the U.S. federal corporate tax rate from 35% to 21% and imposed a new minimum tax on Global Intangible Low-Taxed Income ("GILTI") earned by foreign subsidiaries. In July 2020, final regulations were issued for GILTI, which include a high-tax exception for certain income earned by foreign subsidiaries if the foreign tax rate is in excess of 90% of the U.S. corporate tax rate of 21%. We calculated the potential impact of these final regulations and accounted for those impacts in the quarterly provision for the period ended September 30, 2020.
Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 23.9% and 24.7% for the three months ended December 31, 2020 and 2019, respectively. The effective tax rates used in the calculation of income taxes were 21.1% and 25.2% for the nine months ended December 31, 2020 and 2019, respectively. The decrease in the effective tax rate for the nine months ended December 31, 2020 versus the prior year period was primarily due to the final GILTI regulations issued in July 2020, which resulted in the release of the valuation allowance on foreign tax credit carryforwards of $5.1 million.
-18-

15. Employee Retirement Plans
The primary components of Net Periodic Benefits consist of the following:

|  | Three Months Ended December 31, |  | Nine Months Ended December 31,
(In thousands) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Interest cost |  | $ | 283 |  |  | $ | 575 |  |  | $ | 1,333 |  |  | $ | 1,729 |
Expected return on assets |  | (653) |  |  | (722) |  |  | (1,947) |  |  | (2,164) |
Net periodic benefit income |  | $ | (370) |  |  | $ | (147) |  |  | $ | (614) |  |  | $ | (435) |

During the nine months ended December 31, 2020, we contributed $0.3 million to our non-qualified defined benefit plan and $3.0 million to the qualified defined benefit plan. During the remainder of fiscal 2021, we expect to contribute an additional $0.1 million to our non-qualified plan and make no further contribution to the qualified plan.
During the third quarter of 2021, we offered participants of our qualified defined benefit plan the option to receive a lump sum payout of their benefits. The amount paid out of plan assets during the third quarter of 2021 to those who elected to take the lump sum payout was $7.0 million and we recognized a settlement gain of $0.2 million as a result of the payout.
16. Commitments and Contingencies
We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.
17. Concentrations of Risk
Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and nine months ended December 31, 2020, approximately 43.6% and 45.6%, respectively, of our gross revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2019, approximately 41.7% and 42.8%, respectively of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for the three and nine months ended December 31, 2020. Walmart accounted for approximately 20.7% and 21.7%, respectively, of our gross revenues for the three and nine months ended December 31, 2020. Walmart accounted for approximately 23.2% and 23.4%, respectively, of our gross revenues for the three and nine months ended December 31, 2019.
Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third party distribution manager or COVID-19 or other public health emergencies could also materially impact our product distribution. Any disruption as a result of third party performance at our distribution center could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of the products associated with our acquisition of C.B. Fleet Company, Inc. ("Fleet"), which would also limit our ability to provide those products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations.
At December 31, 2020, we had relationships with 113 third party manufacturers. Of those, we had long-term contracts with 18 manufacturers that produced items that accounted for approximately 68.9% of gross sales for the nine months ended December 31, 2020. At December 31, 2019, we had relationships with 113 third party manufacturers. Of those, we had long-
-19-

term contracts with 17 manufacturers that produced items that accounted for approximately 66.2% of gross sales for the nine months ended December 31, 2019. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.
-20-

18. Business Segments
Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses.
The tables below summarize information about our reportable segments.

| Three Months Ended December 31, 2020
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 210,618 |  |  | $ | 28,170 |  |  |  |  | $ | 238,788 |
Cost of sales | 88,883 |  |  | 11,018 |  |  |  |  | 99,901 |
Gross profit | 121,735 |  |  | 17,152 |  |  |  |  | 138,887 |
Advertising and marketing | 32,859 |  |  | 5,222 |  |  |  |  | 38,081 |
Contribution margin | $ | 88,876 |  |  | $ | 11,930 |  |  |  |  | 100,806 |
Other operating expenses |  |  |  |  |  |  | 27,363 |
Operating income |  |  |  |  |  |  | $ | 73,443 |

* Intersegment revenues of $0.8 million were eliminated from the North American OTC Healthcare segment.

| Nine Months Ended December 31, 2020
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 637,851 |  |  | $ | 67,753 |  |  |  |  | $ | 705,604 |
Cost of sales | 267,779 |  |  | 27,409 |  |  |  |  | 295,188 |
Gross profit | 370,072 |  |  | 40,344 |  |  |  |  | 410,416 |
Advertising and marketing | 91,553 |  |  | 12,619 |  |  |  |  | 104,172 |
Contribution margin | $ | 278,519 |  |  | $ | 27,725 |  |  |  |  | 306,244 |
Other operating expenses |  |  |  |  |  |  | 79,779 |
Operating income |  |  |  |  |  |  | $ | 226,465 |

* Intersegment revenues of $2.4 million were eliminated from the North American OTC Healthcare segment.

| Three Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 214,892 |  |  | $ | 26,660 |  |  |  |  | $ | 241,552 |
Cost of sales | 93,937 |  |  | 10,120 |  |  |  |  | 104,057 |
Gross profit | 120,955 |  |  | 16,540 |  |  |  |  | 137,495 |
Advertising and marketing | 29,025 |  |  | 4,534 |  |  |  |  | 33,559 |
Contribution margin | $ | 91,930 |  |  | $ | 12,006 |  |  |  |  | 103,936 |
Other operating expenses |  |  |  |  |  |  | 27,532 |
Operating income |  |  |  |  |  |  | $ | 76,404 |

* Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.
-21-

| Nine Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 639,554 |  |  | $ | 72,221 |  |  |  |  | $ | 711,775 |
Cost of sales | 275,679 |  |  | 27,783 |  |  |  |  | 303,462 |
Gross profit | 363,875 |  |  | 44,438 |  |  |  |  | 408,313 |
Advertising and marketing | 94,634 |  |  | 12,393 |  |  |  |  | 107,027 |
Contribution margin | $ | 269,241 |  |  | $ | 32,045 |  |  |  |  | 301,286 |
Other operating expenses |  |  |  |  |  |  | 84,048 |
Operating income |  |  |  |  |  |  | $ | 217,238 |

* Intersegment revenues of $2.1 million were eliminated from the North American OTC Healthcare segment.
The tables below summarize information about our segment revenues from similar product groups.

| Three Months Ended December 31, 2020 |
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated |
Analgesics | $ | 29,427 |  |  | $ | 423 |  |  |  |  | $ | 29,850 |  |
Cough & Cold | 16,871 |  |  | 3,877 |  |  |  |  | 20,748 |  |
Women's Health | 60,257 |  |  | 4,229 |  |  |  |  | 64,486 |  |
Gastrointestinal | 31,886 |  |  | 13,436 |  |  |  |  | 45,322 |  |
Eye & Ear Care | 23,166 |  |  | 2,326 |  |  |  |  | 25,492 |  |
Dermatologicals | 24,602 |  |  | 791 |  |  |  |  | 25,393 |  |
Oral Care | 22,907 |  |  | 3,086 |  |  |  |  | 25,993 |  |
Other OTC | 1,502 |  |  | 2 |  |  |  |  | 1,504 |  |
Total segment revenues | $ | 210,618 |  |  | $ | 28,170 |  |  |  |  | $ | 238,788 |  |

| Nine Months Ended December 31, 2020
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 87,917 |  |  | $ | 964 |  |  |  |  | $ | 88,881 |
Cough & Cold | 45,105 |  |  | 10,865 |  |  |  |  | 55,970 |
Women's Health | 187,159 |  |  | 10,766 |  |  |  |  | 197,925 |
Gastrointestinal | 93,654 |  |  | 25,520 |  |  |  |  | 119,174 |
Eye & Ear Care | 72,785 |  |  | 7,908 |  |  |  |  | 80,693 |
Dermatologicals | 80,097 |  |  | 2,326 |  |  |  |  | 82,423 |
Oral Care | 67,017 |  |  | 9,399 |  |  |  |  | 76,416 |
Other OTC | 4,117 |  |  | 5 |  |  |  |  | 4,122 |
Total segment revenues | $ | 637,851 |  |  | $ | 67,753 |  |  |  |  | $ | 705,604 |

-22-

| Three Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 28,330 |  |  | $ | 175 |  |  |  |  | $ | 28,505 |
Cough & Cold | 25,221 |  |  | 4,742 |  |  |  |  | 29,963 |
Women's Health | 58,576 |  |  | 3,543 |  |  |  |  | 62,119 |
Gastrointestinal | 32,645 |  |  | 12,097 |  |  |  |  | 44,742 |
Eye & Ear Care | 24,095 |  |  | 3,159 |  |  |  |  | 27,254 |
Dermatologicals | 23,286 |  |  | 598 |  |  |  |  | 23,884 |
Oral Care | 21,451 |  |  | 2,344 |  |  |  |  | 23,795 |
Other OTC | 1,288 |  |  | 2 |  |  |  |  | 1,290 |
Total segment revenues | $ | 214,892 |  |  | $ | 26,660 |  |  |  |  | $ | 241,552 |

| Nine Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 85,696 |  |  | $ | 648 |  |  |  |  | $ | 86,344 |
Cough & Cold | 63,067 |  |  | 15,938 |  |  |  |  | 79,005 |
Women's Health | 177,832 |  |  | 8,867 |  |  |  |  | 186,699 |
Gastrointestinal | 96,431 |  |  | 28,110 |  |  |  |  | 124,541 |
Eye & Ear Care | 73,134 |  |  | 9,355 |  |  |  |  | 82,489 |
Dermatologicals | 77,063 |  |  | 1,864 |  |  |  |  | 78,927 |
Oral Care | 62,493 |  |  | 7,435 |  |  |  |  | 69,928 |
Other OTC | 3,838 |  |  | 4 |  |  |  |  | 3,842 |
Total segment revenues | $ | 639,554 |  |  | $ | 72,221 |  |  |  |  | $ | 711,775 |

Our total segment revenues by geographic area are as follows:

| Three Months Ended December 31, |  | Nine Months Ended December 31,
| 2020 |  | 2019 |  | 2020 |  | 2019
United States | $ | 197,296 |  |  | $ | 203,920 |  |  | $ | 599,931 |  |  | $ | 604,263 |
Rest of world | 41,492 |  |  | 37,632 |  |  | 105,673 |  |  | 107,512 |
Total | $ | 238,788 |  |  | $ | 241,552 |  |  | $ | 705,604 |  |  | $ | 711,775 |

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:

December 31, 2020 | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
(In thousands) |  |  |  |  |  |  |
Goodwill | $ | 546,643 |  |  | $ | 32,916 |  |  |  |  | $ | 579,559 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,195,617 |  |  | 87,514 |  |  |  |  | 2,283,131 |
Finite-lived, net | 195,248 |  |  | 3,346 |  |  |  |  | 198,594 |
Intangible assets, net | 2,390,865 |  |  | 90,860 |  |  |  |  | 2,481,725 |
Total | $ | 2,937,508 |  |  | $ | 123,776 |  |  |  |  | $ | 3,061,284 |

-23-

March 31, 2020 | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
(In thousands) |  |  |  |  |  |  |
Goodwill | $ | 546,643 |  |  | $ | 28,536 |  |  |  |  | $ | 575,179 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,195,617 |  |  | 69,714 |  |  |  |  | 2,265,331 |
Finite-lived, net | 209,604 |  |  | 4,456 |  |  |  |  | 214,060 |
Intangible assets, net | 2,405,221 |  |  | 74,170 |  |  |  |  | 2,479,391 |
Total | $ | 2,951,864 |  |  | $ | 102,706 |  |  |  |  | $ | 3,054,570 |

-24-

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of our financial condition and results of operations should be read together with the Condensed Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2020. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020 and in future reports filed with the U.S. Securities and Exchange Commission ("SEC").

See also “Cautionary Statement Regarding Forward-Looking Statements” on page 35 of this Quarterly Report on Form 10-Q.

Unless otherwise indicated by the context, all references in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Similarly, reference to a year (e.g., 2021) refers to our fiscal year ended March 31 of that year.
General
We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name over-the-counter ("OTC") healthcare products to mass merchandisers, drug, food, dollar, convenience, and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage.
We have grown our brand portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of OTC brands have also been an important part of our growth strategy. We have acquired strong and well-recognized brands from consumer products and pharmaceutical companies, as well as private equity firms. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a core brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.
Coronavirus Outbreak
In January 2020, the World Health Organization ("WHO") announced a global health crisis due to a new strain of coronavirus ("COVID-19"). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. This pandemic is affecting the United States and global economies, including causing significant volatility in the global economy and resulting in materially reduced economic activity since early 2020. The COVID-19 pandemic and the corresponding government responses have also led to increased unemployment, which led to a reduction in consumer spending. Economic conditions are, and we expect that they will continue to be, highly volatile and uncertain and could continue to reduce demand for our products and put downward pressure on prices. We did see an increase in sales at the end of March 2020 related to shelter-at-home restrictions as we believe consumers stocked up as a result of COVID-19, followed by a temporary but significant decline in consumption in the first quarter. Since then, we have seen more stable consumer consumption and customer orders. Sales have varied throughout the year with some categories positively impacted (for instance, Women’s Health, Oral Care and Dermatological) and some categories negatively impacted (for instance, Cough & Cold, and Gastrointestinal). The positively impacted categories benefited from the consumer shift to over-the-counter healthcare products as consumers increased their focus on hygiene and self-care at home related to COVID-19. The declining categories were impacted by reduced incidence levels and usage rates due to shelter-at-home restrictions and limited travel related to COVID-19. Early in our first quarter of fiscal 2021, we received reports of an increase in absenteeism at our distribution center and with some of our suppliers; however, we have not experienced a material disruption to our overall supply chain to date. We have continued to see changes in the purchasing patterns of our consumers, including the frequency of visits by consumers to retailers and a shift in many markets to purchasing our products online. To date the pandemic has not had a material negative impact on our operations, overall demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change in this dynamic, unprecedented environment. If the outbreak continues to spread, it may materially affect our operations and those of
-25-

third parties on which we rely, including causing disruptions in the supply and distribution of our products. We may need to limit operations and may experience material limitations in employee resources. The extent to which COVID-19 impacts our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, and the actions to contain COVID-19 or treat its impact, among others. We do not yet know the full extent of its impacts on our business or the global economy. However, these effects could have a material, adverse impact on our liquidity, capital resources, and results of operations and those of the third parties on which we rely.
Tax Regulations
On December 22, 2017, the Tax Cuts and Jobs Act was signed into law. The Tax Cuts and Jobs Act, among other things, reduced the U.S. federal corporate tax rate from 35% to 21% and imposed a new minimum tax on Global Intangible Low-Taxed Income ("GILTI") earned by foreign subsidiaries. On July 20, 2020, final regulations were issued for GILTI which include a high-tax exception for income earned by foreign subsidiaries if the foreign tax rate is in excess of 90% of the U.S. tax rate of 21%. We calculated the potential impact of these final regulations and accounted for those impacts in the quarterly provision for the period ended September 30, 2020.
-26-

Results of Operations
Three Months Ended December 31, 2020 compared to the Three Months Ended December 31, 2019
Total Segment Revenues
The following table represents total revenue by segment, including product groups, for the three months ended December 31, 2020 and 2019.

| Three Months Ended December 31, |  |
|  |  |  |  |  |  |  |  | Increase (Decrease) |  |  |
(In thousands) | 2020 |  | % |  | 2019 |  | % |  | Amount |  | % |  |  |
North American OTC Healthcare |  |  |  |  |  |  |  |  |  |  |  |  |
Analgesics | $ | 29,427 |  |  | 12.3 |  |  | $ | 28,330 |  |  | 11.7 |  |  | $ | 1,097 |  |  | 3.9 |  |  |  |
Cough & Cold | 16,871 |  |  | 7.1 |  |  | 25,221 |  |  | 10.4 |  |  | (8,350) |  |  | (33.1) |  |  |  |
Women's Health | 60,257 |  |  | 25.2 |  |  | 58,576 |  |  | 24.3 |  |  | 1,681 |  |  | 2.9 |  |  |  |
Gastrointestinal | 31,886 |  |  | 13.4 |  |  | 32,645 |  |  | 13.5 |  |  | (759) |  |  | (2.3) |  |  |  |
Eye & Ear Care | 23,166 |  |  | 9.7 |  |  | 24,095 |  |  | 10.0 |  |  | (929) |  |  | (3.9) |  |  |  |
Dermatologicals | 24,602 |  |  | 10.3 |  |  | 23,286 |  |  | 9.6 |  |  | 1,316 |  |  | 5.7 |  |  |  |
Oral Care | 22,907 |  |  | 9.6 |  |  | 21,451 |  |  | 8.9 |  |  | 1,456 |  |  | 6.8 |  |  |  |
Other OTC | 1,502 |  |  | 0.6 |  |  | 1,288 |  |  | 0.5 |  |  | 214 |  |  | 16.7 |  |  |  |
Total North American OTC Healthcare | 210,618 |  |  | 88.2 |  |  | 214,892 |  |  | 88.9 |  |  | (4,274) |  |  | (2.0) |  |  |  |
International OTC Healthcare |  |  |  |  |  |  |  |  |  |  |  |  |
Analgesics | 423 |  |  | 0.2 |  |  | 175 |  |  | 0.1 |  |  | 248 |  |  | 141.7 |  |  |  |
Cough & Cold | 3,877 |  |  | 1.6 |  |  | 4,742 |  |  | 2.0 |  |  | (865) |  |  | (18.2) |  |  |  |
Women's Health | 4,229 |  |  | 1.8 |  |  | 3,543 |  |  | 1.5 |  |  | 686 |  |  | 19.4 |  |  |  |
Gastrointestinal | 13,436 |  |  | 5.6 |  |  | 12,097 |  |  | 5.0 |  |  | 1,339 |  |  | 11.1 |  |  |  |
Eye & Ear Care | 2,326 |  |  | 1.0 |  |  | 3,159 |  |  | 1.3 |  |  | (833) |  |  | (26.4) |  |  |  |
Dermatologicals | 791 |  |  | 0.3 |  |  | 598 |  |  | 0.2 |  |  | 193 |  |  | 32.3 |  |  |  |
Oral Care | 3,086 |  |  | 1.3 |  |  | 2,344 |  |  | 1.0 |  |  | 742 |  |  | 31.7 |  |  |  |
Other OTC | 2 |  |  | — |  |  | 2 |  |  | — |  |  | — |  |  | — |  |  |  |
Total International OTC Healthcare | 28,170 |  |  | 11.8 |  |  | 26,660 |  |  | 11.1 |  |  | 1,510 |  |  | 5.7 |  |  |  |
Total Consolidated | $ | 238,788 |  |  | 100.0 |  |  | $ | 241,552 |  |  | 100.0 |  |  | $ | (2,764) |  |  | (1.1) |  |  |  |

Total segment revenues for the three months ended December 31, 2020 were $238.8 million, a decrease of $2.8 million, or 1.1%, versus the three months ended December 31, 2019. The $2.8 million decrease was related to the decrease in our North American OTC Healthcare segment, partly offset by an increase in our International OTC Healthcare segment.
North American OTC Healthcare Segment
Revenues for the North American OTC Healthcare segment decreased $4.3 million, or 2.0%, during the three months ended December 31, 2020 versus the three months ended December 31, 2019. The three months ended December 31, 2020 were negatively impacted by the Cough & Cold category, but were partly offset by the higher Women’s Health and Oral Care revenues. The Cough & Cold category was impacted by reduced incidence levels and usage rates due to shelter-at-home restrictions and limited travel related to COVID-19. The positively impacted categories benefited from the consumer shift to over-the-counter healthcare products as consumers increased their focus on hygiene and self-care at home related to COVID-19.
International OTC Healthcare Segment
Revenues for the International OTC Healthcare segment increased $1.5 million, or 5.7%, during the three months ended December 31, 2020 versus the three months ended December 31, 2019. The $1.5 million increase was attributable to increased sales in our Australian subsidiary primarily related to increase in sales of Hydralyte. The increase in sales of Hydralyte was related to an easing of shelter-at-home restrictions in Australia.
-27-

Gross Profit
The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.

| Three Months Ended December 31,
(In thousands) |  |  |  |  |  |  |  |  | Increase (Decrease)
Gross Profit | 2020 |  | % |  | 2019 |  | % |  | Amount |  | %
North American OTC Healthcare | $ | 121,735 |  |  | 57.8 |  |  | $ | 120,955 |  |  | 56.3 |  |  | $ | 780 |  |  | 0.6 |
International OTC Healthcare | 17,152 |  |  | 60.9 |  |  | 16,540 |  |  | 62.0 |  |  | 612 |  |  | 3.7 |
| $ | 138,887 |  |  | 58.2 |  |  | $ | 137,495 |  |  | 56.9 |  |  | $ | 1,392 |  |  | 1.0 |

Gross profit for the three months ended December 31, 2020 was relatively flat, increasing $1.4 million, or 1.0%, when compared with the three months ended December 31, 2019. As a percentage of total revenues, gross profit increased to 58.2% during the three months ended December 31, 2020, from 56.9% during the three months ended December 31, 2019. The increase in gross profit as a percentage of revenues was primarily a result of the fourth quarter 2020 completion of transitional costs associated with a new warehouse and distribution center.
North American OTC Healthcare Segment
Gross profit for the North American OTC Healthcare segment increased $0.8 million, or 0.6%, during the three months ended December 31, 2020 versus the three months ended December 31, 2019. As a percentage of North American OTC Healthcare revenues, gross profit increased to 57.8% during the three months ended December 31, 2020 from 56.3% during the three months ended December 31, 2019, primarily due to the fourth quarter 2020 completion of transitional costs associated with a new warehouse and distribution center and improved logistics costs resulting from our warehouse transition.
International OTC Healthcare Segment
Gross profit for the International OTC Healthcare segment increased $0.6 million, or 3.7%, during the three months ended December 31, 2020 versus the three months ended December 31, 2019. As a percentage of International OTC Healthcare revenues, gross profit decreased to 60.9% during the three months ended December 31, 2020 from 62.0% during the three months ended December 31, 2019, primarily due to product mix.
Contribution Margin
Contribution margin is our segment measure of profitability. It is defined as gross profit less advertising and marketing expenses.
The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.

| Three Months Ended December 31,
(In thousands) |  |  |  |  |  |  |  |  | Increase (Decrease)
Contribution Margin | 2020 |  | % |  | 2019 |  | % |  | Amount |  | %
North American OTC Healthcare | $ | 88,876 |  |  | 42.2 |  |  | $ | 91,930 |  |  | 42.8 |  |  | $ | (3,054) |  |  | (3.3) |
International OTC Healthcare | 11,930 |  |  | 42.4 |  |  | 12,006 |  |  | 45.0 |  |  | (76) |  |  | (0.6) |
| $ | 100,806 |  |  | 42.2 |  |  | $ | 103,936 |  |  | 43.0 |  |  | $ | (3,130) |  |  | (3.0) |

North American OTC Healthcare Segment
Contribution margin for the North American OTC Healthcare segment decreased $3.1 million, or 3.3%, during the three months ended December 31, 2020 versus the three months ended December 31, 2019. As a percentage of North American OTC Healthcare revenues, contribution margin decreased to 42.2% during the three months ended December 31, 2020 from 42.8% during the three months ended December 31, 2019. The contribution margin decrease as a percentage of revenues was primarily due to an increase in advertising and marketing expenses, partly offset by the increase in gross profit noted above.
International OTC Healthcare Segment
Contribution margin for the International OTC Healthcare segment decreased $0.1 million, or 0.6%, during the three months ended December 31, 2020 versus the three months ended December 31, 2019. As a percentage of International OTC
-28-

Healthcare revenues, contribution margin decreased to 42.4% during the three months ended December 31, 2020 from 45.0% during the three months ended December 31, 2019. The contribution margin decrease as a percentage of revenues was due to a decrease in gross profit noted above as well as incremental advertising and marketing expense.
General and Administrative
General and administrative expenses of $21.4 million for the three months ended December 31, 2020 were relatively flat versus $21.3 million for the three months ended December 31, 2019.
Depreciation and Amortization
Depreciation and amortization expenses were $6.0 million for the three months ended December 31, 2020 and $6.2 million for the three months ended December 31, 2019. The decrease in depreciation and amortization was primarily due to certain assets being fully depreciated in the first quarter of fiscal 2021.
Interest Expense, Net
Interest expense, net was $20.1 million during the three months ended December 31, 2020, versus $24.3 million during the three months ended December 31, 2019. The average indebtedness decreased to $1.6 billion during the three months ended December 31, 2020 from $1.8 billion during the three months ended December 31, 2019. The average cost of borrowing decreased to 5.1% for the three months ended December 31, 2020 from 5.4% for the three months ended December 31, 2019.
Loss on Extinguishment of Debt
During the three months ended December 31, 2019, we recorded a loss on extinguishment of debt of $2.2 million to write off the debt costs related to our 5.375% 2013 Senior Notes, which we redeemed in December 2019.
Income Taxes
The provision for income taxes during the three months ended December 31, 2020 was $12.8 million versus $12.5 million during the three months ended December 31, 2019. The effective tax rate during the three months ended December 31, 2020 was 23.9% versus 24.7% during the three months ended December 31, 2019. The decrease in the effective tax rate for the three months ended December 31, 2020 was based on our estimated annual effective income tax rate which fluctuates based on the mix of earnings from our U.S. and foreign jurisdictions.
-29-

Results of Operations
Nine Months Ended December 31, 2020 compared to the Nine Months Ended December 31, 2019
Total Segment Revenues
The following table represents total revenue by segment, including product groups, for the nine months ended December 31, 2020 and 2019.

| Nine Months Ended December 31, |  |
|  |  |  |  |  |  |  |  | Increase (Decrease) |  |  |
(In thousands) | 2020 |  | % |  | 2019 |  | % |  | Amount |  | % |  |  |
North American OTC Healthcare |  |  |  |  |  |  |  |  |  |  |  |  |
Analgesics | $ | 87,917 |  |  | 12.5 |  |  | $ | 85,696 |  |  | 12.0 |  |  | $ | 2,221 |  |  | 2.6 |  |  |  |
Cough & Cold | 45,105 |  |  | 6.4 |  |  | 63,067 |  |  | 8.9 |  |  | (17,962) |  |  | (28.5) |  |  |  |
Women's Health | 187,159 |  |  | 26.4 |  |  | 177,832 |  |  | 25.2 |  |  | 9,327 |  |  | 5.2 |  |  |  |
Gastrointestinal | 93,654 |  |  | 13.3 |  |  | 96,431 |  |  | 13.5 |  |  | (2,777) |  |  | (2.9) |  |  |  |
Eye & Ear Care | 72,785 |  |  | 10.3 |  |  | 73,134 |  |  | 10.3 |  |  | (349) |  |  | (0.5) |  |  |  |
Dermatologicals | 80,097 |  |  | 11.4 |  |  | 77,063 |  |  | 10.8 |  |  | 3,034 |  |  | 3.9 |  |  |  |
Oral Care | 67,017 |  |  | 9.5 |  |  | 62,493 |  |  | 8.8 |  |  | 4,524 |  |  | 7.2 |  |  |  |
Other OTC | 4,117 |  |  | 0.6 |  |  | 3,838 |  |  | 0.5 |  |  | 279 |  |  | 7.3 |  |  |  |
Total North American OTC Healthcare | 637,851 |  |  | 90.4 |  |  | 639,554 |  |  | 90.0 |  |  | (1,703) |  |  | (0.3) |  |  |  |
International OTC Healthcare |  |  |  |  |  |  |  |  |  |  |  |  |
Analgesics | 964 |  |  | 0.1 |  |  | 648 |  |  | 0.1 |  |  | 316 |  |  | 48.8 |  |  |  |
Cough & Cold | 10,865 |  |  | 1.5 |  |  | 15,938 |  |  | 2.2 |  |  | (5,073) |  |  | (31.8) |  |  |  |
Women's Health | 10,766 |  |  | 1.6 |  |  | 8,867 |  |  | 1.2 |  |  | 1,899 |  |  | 21.4 |  |  |  |
Gastrointestinal | 25,520 |  |  | 3.7 |  |  | 28,110 |  |  | 3.9 |  |  | (2,590) |  |  | (9.2) |  |  |  |
Eye & Ear Care | 7,908 |  |  | 1.1 |  |  | 9,355 |  |  | 1.3 |  |  | (1,447) |  |  | (15.5) |  |  |  |
Dermatologicals | 2,326 |  |  | 0.3 |  |  | 1,864 |  |  | 0.3 |  |  | 462 |  |  | 24.8 |  |  |  |
Oral Care | 9,399 |  |  | 1.3 |  |  | 7,435 |  |  | 1.0 |  |  | 1,964 |  |  | 26.4 |  |  |  |
Other OTC | 5 |  |  | — |  |  | 4 |  |  | — |  |  | 1 |  |  | 25.0 |  |  |  |
Total International OTC Healthcare | 67,753 |  |  | 9.6 |  |  | 72,221 |  |  | 10.0 |  |  | (4,468) |  |  | (6.2) |  |  |  |
Total Consolidated | $ | 705,604 |  |  | 100.0 |  |  | $ | 711,775 |  |  | 100.0 |  |  | $ | (6,171) |  |  | (0.9) |  |  |  |

Total segment revenues for the nine months ended December 31, 2020 were $705.6 million, a decrease of $6.2 million, or 0.9%, versus the nine months ended December 31, 2019. The $6.2 million decrease was primarily related to our International OTC Healthcare segment.
North American OTC Healthcare Segment
Revenues for the North American OTC Healthcare segment decreased $1.7 million, or 0.3%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. The nine months ended December 31, 2020 were negatively impacted by lower Cough & Cold and Gastrointestinal revenues, partly offset by positively impacted Women’s Health and Oral Care categories. The Cough & Cold and Gastrointestinal categories faced declines in incidence levels and usage rates due to shelter-at-home restrictions and limited travel related to COVID-19. The positively impacted categories benefited from the consumer shift to over-the-counter healthcare products as consumers increased their focus on hygiene and self-care at home related to COVID-19.
International OTC Healthcare Segment
Revenues for the International OTC Healthcare segment decreased $4.5 million, or 6.2%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. The $4.5 million decrease was primarily attributable to decreased sales in our Australian subsidiary, primarily related to both lower general consumer illnesses and activities such as athletics resulting from the various social distancing measures brought on by COVID-19.
-30-

Gross Profit
The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.

| Nine Months Ended December 31,
(In thousands) |  |  |  |  |  |  |  |  | Increase (Decrease)
Gross Profit | 2020 |  | % |  | 2019 |  | % |  | Amount |  | %
North American OTC Healthcare | $ | 370,072 |  |  | 58.0 |  |  | $ | 363,875 |  |  | 56.9 |  |  | $ | 6,197 |  |  | 1.7 |
International OTC Healthcare | 40,344 |  |  | 59.5 |  |  | 44,438 |  |  | 61.5 |  |  | (4,094) |  |  | (9.2) |
| $ | 410,416 |  |  | 58.2 |  |  | $ | 408,313 |  |  | 57.4 |  |  | $ | 2,103 |  |  | 0.5 |

Gross profit for the nine months ended December 31, 2020 increased $2.1 million, or 0.5%, when compared with the nine months ended December 31, 2019. The increase in gross profit was due to the increase in the North American OTC Healthcare segment. As a percentage of total revenues, gross profit increased to 58.2% during the nine months ended December 31, 2020, from 57.4% during the nine months ended December 31, 2019. The increase in gross profit as a percentage of revenues was primarily a result of the fourth quarter 2020 completion of transitional costs associated with a new warehouse and distribution center and improved logistics costs resulting from our warehouse transition.
North American OTC Healthcare Segment
Gross profit for the North American OTC Healthcare segment increased $6.2 million, or 1.7%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. As a percentage of North American OTC Healthcare revenues, gross profit increased to 58.0% during the nine months ended December 31, 2020 from 56.9% during the nine months ended December 31, 2019, primarily due to the fourth quarter completion of transitional costs associated with a new warehouse and distribution center and improved logistics costs resulting from our warehouse transition.
International OTC Healthcare Segment
Gross profit for the International OTC Healthcare segment decreased $4.1 million, or 9.2%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. As a percentage of International OTC Healthcare revenues, gross profit decreased to 59.5% during the nine months ended December 31, 2020 from 61.5% during the nine months ended December 31, 2019, primarily due to product mix.
Contribution Margin
Contribution margin is our segment measure of profitability. It is defined as gross profit less advertising and marketing expenses.
The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.

| Nine Months Ended December 31,
(In thousands) |  |  |  |  |  |  |  |  | Increase (Decrease)
Contribution Margin | 2020 |  | % |  | 2019 |  | % |  | Amount |  | %
North American OTC Healthcare | $ | 278,519 |  |  | 43.7 |  |  | $ | 269,241 |  |  | 42.1 |  |  | $ | 9,278 |  |  | 3.4 |
International OTC Healthcare | 27,725 |  |  | 40.9 |  |  | 32,045 |  |  | 44.4 |  |  | (4,320) |  |  | (13.5) |
| $ | 306,244 |  |  | 43.4 |  |  | $ | 301,286 |  |  | 42.3 |  |  | $ | 4,958 |  |  | 1.6 |

North American OTC Healthcare Segment
Contribution margin for the North American OTC Healthcare segment increased $9.3 million, or 3.4%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. As a percentage of North American OTC Healthcare revenues, contribution margin increased to 43.7% during the nine months ended December 31, 2020 from 42.1% during the nine months ended December 31, 2019. The contribution margin increase as a percentage of revenues was primarily due to the increase in gross profit noted above as well as a decrease in the first quarter of 2021 in advertising and marketing reflecting spend efficiencies and reductions across brands/categories driven by consumer behavior.
International OTC Healthcare Segment
Contribution margin for the International OTC Healthcare segment decreased $4.3 million, or 13.5%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. As a percentage of International OTC Healthcare revenues, contribution margin decreased to 40.9% during the nine months ended December 31, 2020 from 44.4% during the
-31-

nine months ended December 31, 2019. The contribution margin decrease as a percentage of revenues was primarily due to the decrease in gross profit noted above.
General and Administrative
General and administrative expenses decreased $3.8 million, or 5.8%, during the nine months ended December 31, 2020 versus the nine months ended December 31, 2019. The decrease in general and administrative expenses was primarily due to decreases in compensation costs resulting from attrition as well as reduced travel costs relating to COVID-19.
Depreciation and Amortization
Depreciation and amortization expenses were $18.1 million for the nine months ended December 31, 2020 and $18.5 million for the nine months ended December 31, 2019. The decrease in depreciation and amortization expenses was primarily due to certain assets being fully depreciated in the first quarter of fiscal 2021.
Interest Expense, Net
Interest expense, net was $63.3 million during the nine months ended December 31, 2020, versus $73.8 million during the nine months ended December 31, 2019. The average indebtedness decreased to $1.6 billion during the nine months ended December 31, 2020 from $1.8 billion during the nine months ended December 31, 2019. The average cost of borrowing decreased to 5.1% for the nine months ended December 31, 2020 from 5.4% for the nine months ended December 31, 2019.
Loss on Extinguishment of Debt
During the nine months ended December 31, 2019, we recorded a loss on extinguishment of debt of $2.2 million to write off the debt costs related to our 5.375% 2013 Senior Notes, which we redeemed in December 2019.
Income Taxes
The provision for income taxes during the nine months ended December 31, 2020 was $34.6 million versus $35.4 million during the nine months ended December 31, 2019. The effective tax rate during the nine months ended December 31, 2020 was 21.1% versus 25.2% during the nine months ended December 31, 2019. The decrease in the effective tax rate for the nine months ended December 31, 2020 was primarily due to the application of final tax regulations issued for GILTI, and the discrete event pertaining to the release of the valuation allowance on prior year foreign tax credits.
Liquidity and Capital Resources
Liquidity
Our primary source of cash comes from our cash flow from operations. In the past, we have supplemented this source of cash with various debt facilities, primarily in connection with acquisitions. We have financed our operations, and expect to continue to finance our operations over the next twelve months, with a combination of funds generated from operations and borrowings. Our principal uses of cash are for operating expenses, debt service, share repurchases, capital expenditures, and acquisitions. Based on our current levels of operations and anticipated growth, excluding acquisitions, we believe that our cash generated from operations and our existing credit facilities will be adequate to finance our working capital and capital expenditures through the next twelve months. See "Coronavirus Outbreak" above.
As of December 31, 2020, we had cash and cash equivalents of $62.1 million, a decrease of $32.7 million from March 31, 2020. The following table summarizes the change:

| Nine Months Ended December 31,
(In thousands) | 2020 |  | 2019 |  | $ Change
Cash provided by (used in): |  |  |  |  |
Operating Activities | $ | 176,520 |  |  | $ | 160,998 |  |  | $ | 15,522 |
Investing Activities | (17,347) |  |  | (8,305) |  |  | (9,042) |
Financing Activities | (195,710) |  |  | (151,988) |  |  | (43,722) |
Effects of exchange rate changes on cash and cash equivalents | 3,880 |  |  | 356 |  |  | 3,524 |
Net change in cash and cash equivalents | $ | (32,657) |  |  | $ | 1,061 |  |  | $ | (33,718) |

Operating Activities
Net cash provided by operating activities was $176.5 million for the nine months ended December 31, 2020, compared to $161.0 million for the nine months ended December 31, 2019. The $15.5 million increase was due to an increase in net income after non-cash items partly offset by increased working capital.
-32-

Investing Activities
Net cash used in investing activities was $17.3 million for the nine months ended December 31, 2020, compared to $8.3 million for the nine months ended December 31, 2019. The increase was due to an increase in capital expenditures in the current period.
Financing Activities
Net cash used in financing activities was $195.7 million for the nine months ended December 31, 2020, compared to $152.0 million for the nine months ended December 31, 2019. The increase was primarily due to increased repayments of debt of $59.0 million and decreased borrowings of $30.0 million in the nine months ended December 31, 2020, partly offset by a decrease in our repurchase of common stock of $40.1 million compared to the prior period as well as a payment of debt costs of $5.8 million in the nine months ended December 31, 2019.
Capital Resources
As of December 31, 2020, we had an aggregate of $1.6 billion of outstanding indebtedness, which consisted of the following:
•$400.0 million of 5.125% 2019 Senior Notes, which mature on January 15, 2028;
•$600.0 million of 6.375% 2016 Senior Notes, which mature on March 1, 2024; and
•$560.0 million of borrowings under the 2012 Term B-5 Loans due January 26, 2024.
As of December 31, 2020, we had no balance outstanding on 2012 ABL Revolver and a borrowing capacity of $123.3 million.
During the years ended March 31, 2020 and 2019, under the 2012 Term Loan, we made voluntary principal payments against outstanding indebtedness of $48.0 million and $200.0 million, respectively. During the nine months ended December 31, 2020, we made voluntary principal payments against outstanding indebtedness of $130.0 million under the 2012 Term Loan. Under the Term Loan Amendment No. 5, we are required to make quarterly payments each equal to 0.25% of the aggregate principal amount, which, as of December 31, 2020, was $560.0 million. Since we have made optional payments this year and in prior years that exceed a significant portion of our required quarterly payments, we will not be required to make another payment on the 2012 Term Loan until maturity on January 26, 2024.
Maturities:

(In thousands) |
Year Ending March 31, | Amount
2021 (remaining three months ending March 31, 2021) | $ | — |
2022 |  | — |
2023 |  | — |
2024 |  | 1,160,000 |
2025 |  | — |
Thereafter | 400,000 |
| $ | 1,560,000 |

Covenants:
Our debt facilities contain various financial covenants, including provisions that require us to maintain certain leverage, interest coverage and fixed charge ratios. The credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and 2019 Senior Notes contain provisions that accelerate our indebtedness on certain changes in control and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payments of dividends and other specified payments, repurchasing our equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transactions with affiliates. Specifically, we must:
•Have a leverage ratio of less than 6.50 to 1.0 for the quarter ended December 31, 2020 and thereafter (defined as, with certain adjustments, the ratio of our consolidated total net debt as of the last day of the fiscal quarter to our trailing twelve month consolidated net income before interest, taxes, depreciation, amortization, non-cash charges and certain other items (“EBITDA”));
-33-

•Have an interest coverage ratio of greater than 2.25 to 1.0 for the quarter ended December 31, 2020 and thereafter (defined as, with certain adjustments, the ratio of our consolidated EBITDA to our trailing twelve month consolidated cash interest expense); and
•Have a fixed charge ratio of greater than 1.0 to 1.0 for the quarter ended December 31, 2020 (defined as, with certain adjustments, the ratio of our consolidated EBITDA minus capital expenditures to our trailing twelve month consolidated interest paid, taxes paid and other specified payments). Our fixed charge requirement remains level throughout the term of the debt facilities.
At December 31, 2020, we were in compliance with the applicable financial and restrictive covenants under the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2019 Senior Notes. Additionally, management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during the next twelve months.
Interest Rate Swaps:
We have had two interest rate swaps to hedge a total of $400.0 million of our variable interest debt. Of these, $200.0 million matured on January 31, 2021 and $200.0 million matures on January 31, 2022.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements or financing activities with special-purpose entities.
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. A summary of our critical accounting policies is presented in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020. There were no material changes to our critical accounting policies during the nine months ended December 31, 2020.
Recent Accounting Pronouncements
A description of recently issued and recently adopted accounting pronouncements is included in the notes to the unaudited Condensed Consolidated Financial Statements in Part I, Item I, Note 1 of this Quarterly Report on Form 10-Q.
-34-

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the “safe harbor” provisions of the PSLRA.
Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required under federal securities laws and the rules and regulations of the SEC, we do not intend to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.
These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “anticipate,” “expect,” “estimate,” “project,” "intend," "strategy," "goal," "future," "seek," "may," "should," "would," "will," or other similar words and phrases. Forward-looking statements are based on current expectations and assumptions that are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation:
•The impact of the COVID-19 pandemic or other disease outbreaks on global economic conditions, consumer demand, retailer product availability, and business operations including manufacturing, supply chain and distribution;
•The high level of competition in our industry and markets;
•Our inability to increase organic growth via new product introductions, line extensions, increased spending on advertising and marketing support, and other new sales and marketing strategies;
•Our dependence on a limited number of customers for a large portion of our sales;
•Our inability to successfully identify, negotiate, complete and integrate suitable acquisition candidates and to obtain necessary financing;
•Our inability to invest successfully in research and development to develop new products;
•Changes in inventory management practices by retailers;
•Our inability to grow our international sales;
•General economic conditions and incidence levels affecting sales of our products and their respective markets;
•Economic factors, such as increases in interest rates and currency exchange rate fluctuations;
•Changing consumer trends, additional store brand or branded competition or other pricing pressures which may cause us to lower our prices;
•Our dependence on third party manufacturers to produce many of the products we sell;
•Our dependence on third party logistics providers to distribute our products to customers;
•Price increases for raw materials, labor, energy and transportation costs, and for other input costs;
•Disruptions in our distribution center or manufacturing facility;
•Shortages of supply of sourced goods;
•Acquisitions, dispositions or other strategic transactions diverting managerial resources, the incurrence of additional liabilities or problems associated with integration of those businesses and facilities;
•Actions of government agencies in connection with our products, advertising or regulatory matters governing our industry;
•Product liability claims, product recalls and related negative publicity;
•Our inability to protect our intellectual property rights;
•Our dependence on third parties for intellectual property relating to some of the products we sell;
•Our inability to protect our internal information technology systems;
•Our dependence on third party information technology service providers and their ability to protect against security threats and disruptions;
•Our assets being comprised virtually entirely of goodwill and intangibles and possible changes in their value based on adverse operating results and/or changes in the discount rate used to value our brands;
•Our dependence on key personnel;
•The costs associated with any claims in litigation or arbitration and any adverse judgments rendered in such litigation or arbitration;
•Our level of indebtedness and possible inability to service our debt;
•Our inability to obtain additional financing;
•The restrictions imposed by our financing agreements on our operations; and
•Changes in federal, state and other geographic tax laws.
-35-

For more information, see Part I, Item 1A., "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.
-36-

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk
We are exposed to changes in interest rates because our 2012 Term Loan and 2012 ABL Revolver are variable rate debt. To manage this risk, we use interest rate swaps to hedge a total of $400.0 million of this variable rate debt. At December 31, 2020, approximately $160.0 million of our debt carries a variable rate of interest.
Holding other variables constant, including levels of indebtedness, a 1.0% increase in interest rates on our variable rate debt would have an adverse impact on pre-tax earnings and cash flows for the three and nine months ended December 31, 2020 of approximately $0.4 million and $1.8 million, respectively.
Foreign Currency Exchange Rate Risk
During the three and nine months ended December 31, 2020, approximately 13.9% and 11.7%, respectively, of our gross revenues were denominated in currencies other than the U.S. Dollar. During the three and nine months ended December 31, 2019, approximately 12.7% and 11.6%, respectively, of our gross revenues were denominated in currencies other than the U.S. Dollar. As such, we are exposed to transactions that are sensitive to foreign currency exchange rates. These transactions are primarily with respect to the Canadian and Australian Dollars.
We performed a sensitivity analysis with respect to exchange rates for the three and nine months ended December 31, 2020 and 2019. Holding all other variables constant, and assuming a hypothetical 10.0% adverse change in foreign currency exchange rates, this analysis resulted in a less than 5.0% impact on pre-tax income of approximately $1.2 million for the three months ended December 31, 2020 and approximately $3.2 million for the nine months ended December 31, 2020. It represented a less than 5% impact on pre-tax income of approximately $1.4 million for the three months ended December 31, 2019 and approximately $4.0 million for the nine months ended December 31, 2019.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of December 31, 2020. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2020, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
-37-

PART II. OTHER INFORMATION
ITEM 1A. RISK FACTORS
You should carefully consider the risk factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended March 31, 2020, which could materially affect our business, financial condition or future results of operations. The risk factors described in our Annual Report on Form 10-K have not materially changed in the period covered by this Quarterly Report on Form 10-Q, but such risks are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations.
Our quarterly operating results and revenues may fluctuate as a result of any of these or other factors. Accordingly, results for any one quarter are not necessarily indicative of results to be expected for any other quarter or for any year, and revenues for any particular future period may decrease. In the future, operating results may fall below the expectations of securities analysts and investors. In that event, the market price of our outstanding securities could be adversely impacted.
ITEM 2. ISSUER PURCHASES OF EQUITY SECURITIES

Period |  | Total Number of Shares Purchased (a) |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
October 1 to October 31, 2020 |  | 58,522 |  |  | $ | 34.04 |  |  | 58,522 |  |  | $ | 15,265,264 |
November 1 to November 30, 2020 |  | 73,510 |  |  | $ | 33.96 |  |  | 73,510 |  |  | $ | 12,769,191 |
December 1 to December 31, 2020 |  | 121,739 |  |  | $ | 36.05 |  |  | 121,739 |  |  | $ | 8,380,911 |
Total |  | 253,771 |  |  |  |  | 253,771 |  |  |

(a) These repurchases were made pursuant to our share repurchase program, which was announced on March 2, 2020 and permits the repurchase of up to $25.0 million of our common stock through March 2021.
-38-

ITEM 6. EXHIBITS

3.1 |  | Amended and Restated Certificate of Incorporation of Prestige Consumer Healthcare Inc. (filed as Exhibit 3.1 to the Company's Form S-1/A filed with the SEC on February 8, 2005).*
3.1.1 |  | Amendment to Amended and Restated Certificate of Incorporation of Prestige Consumer Healthcare Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 2, 2018).*
3.2 |  | Amended and Restated Bylaws of Prestige Consumer Healthcare Inc., as amended, effective October 29, 2018 (filed as Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on February 7, 2019).*
31.1 |  | Certification of Principal Executive Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
31.2 |  | Certification of Principal Financial Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
32.1 |  | Certification of Principal Executive Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
32.2 |  | Certification of Principal Financial Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
* |  | Incorporated herein by reference.
101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH |  | XBRL Taxonomy Extension Schema Document
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document

-39-

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | PRESTIGE CONSUMER HEALTHCARE INC. |
Date: | February 4, 2021 | By: | /s/ Christine Sacco |
|  |  | Christine Sacco |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer and Duly Authorized Officer) |

-40-